{
  "$schema": "folio-library-entry/v1",
  "id": "10665-44118",
  "blocks": [
    {
      "id": "library/10665-44118/blocks/prose-sec-front-matter",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Front matter",
      "pageStart": 1,
      "pageEnd": 10,
      "target": "../sections/sec-front-matter.md",
      "narrative": null,
      "content": "Casebook on \nEthical Issues \nin International \nHealth Research\nEditors:\nRichard Cash\nDaniel Wikler\nAbha Saxena\nAlexander Capron\nCasebook on Ethical \nIssues in International \nHealth Research\nEditors:\nRichard Cash \nDaniel Wikler \nAbha Saxena \nAlexander Capron\nAssociate editor:\nReva Gutnick\nEditorial guidance provided by  \nAstrid Stuckelberger and Philippe Chastonay, University of Geneva\nCASEBOOK ON ETHICAL ISSUES IN INTERNATIONAL HEALTH RESEARCH\nWHO Library Cataloguing-in-Publication Data\nCasebook on ethical issues in international health research / edited by  Richard Cash …  [et al].\n1.Ethics,",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Front matter of the WHO Casebook on Ethical Issues in International Health Research (2009), giving the title, the four editors and the associate editor, cataloguing data with the ISBN, and the copyright and disclaimer notice. A short note explains that the casebook is meant for instructors and workshop leaders, who may photocopy or download individual cases for non-commercial teaching as long as WHO is acknowledged. The table of contents then lists the introductory sections, the 64 case studies grouped into thematic chapters, a glossary, suggested readings and an appendix.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-44118/blocks/prose-sec-000",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Acknowledgements",
      "pageStart": 10,
      "pageEnd": 11,
      "target": "../sections/sec-000-acknowledgements.md",
      "narrative": null,
      "content": "This casebook is the result of a collaborative effort titled “the \nResearch Ethics Training Project” between the World Health \nOrganization and the University of Geneva undertaken \nwith the generous financial support of Réseau universitaire \ninternational de Genève/Geneva International Academic \nNetwork (RUIG/GIAN). \nMany people have shared their time, energy and expertise \nin the development of this casebook. Philippe Chastonay \nand Astrid  Stuckelberger of the Department of Social \nand Community Health at the Faculty of Medicine of the \nUniversity of Geneva were involved in the initial brain",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Acknowledgements for the casebook, which grew out of a Research Ethics Training Project between WHO and the University of Geneva funded by the Geneva International Academic Network (RUIG/GIAN). The editors thank the people who proposed or wrote case studies, including teams from Johns Hopkins University, the Sri Lanka Twin Registry and a 2004 Bangkok workshop of the special programme on human reproduction. They also credit workshop facilitators, online course tutors, international reviewers, editorial interns and the designers, and sign the text in March 2009.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-44118/blocks/prose-sec-001",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Foreword",
      "pageStart": 11,
      "pageEnd": 12,
      "target": "../sections/sec-001-foreword.md",
      "narrative": null,
      "content": "CASEBOOK ON ETHICAL ISSUES IN INTERNATIONAL HEALTH RESEARCH\nFor the World Health Organization, research is a vital ingredi-\nent for improved global health. Our dedication to producing \nand using knowledge to improve human health is itself \ngrounded on an ethical commitment: that such research is \ncarried out ethically and offers the prospect of raising the \nstandard of health for everyone. \nOne of the essential components of health research is a strong \nset of ethical standards, well understood and applied by \nresearch teams and sponsors. Examination of, and education \nabout, the ethical issue",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The foreword, by WHO Assistant Director-General Timothy Evans, states that sound ethical standards are an essential part of health research and that WHO is stepping up efforts to ensure they are met, especially in resource-poor settings where local researchers and ethics committees must be able to recognise and handle ethical issues. It explains that the casebook, developed under the lead of WHO's Ethics Review Committee, uses cases based on real studies for individual reading or group discussion as an effective way to learn to apply ethical principles.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-44118/blocks/prose-sec-002",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "The editors",
      "pageStart": 12,
      "pageEnd": 13,
      "target": "../sections/sec-002-the-editors.md",
      "narrative": null,
      "content": "Richard A. Cash MD, MPH, is a Senior Lecturer in the \nDepartment of Global Health and Population at the Harvard \nSchool of Public Health (HSPH). He is the Director of the \nProgram on Ethical Issues in Global Health Research at \nHSPH. Dr Cash has been involved in international health \nfor over 40 years as a researcher, a funder and developer \nof health research projects, and as a visiting faculty at a \nnumber of schools of public health around the world. \nHe has conducted numerous research ethics workshops \nthroughout Latin America, Africa, and Asia. Dr Cash began \nhis research career in what i",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Gives short biographies of the four editors: Richard Cash and Daniel Wikler of the Harvard School of Public Health, Abha Saxena, who manages the WHO Research Ethics Review Committee, and Alex Capron of the University of Southern California. It highlights their research, teaching and leadership roles in global health and bioethics, including Cash's early oral rehydration therapy trials and the former WHO ethics posts held by Wikler and Capron.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-44118/blocks/figure-img-p013-1",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 13,
      "pageEnd": 13,
      "target": "../images/img-p013-1.webp",
      "narrative": "draft",
      "content": "Sepia-toned photograph of a smiling young child with wet hair, arms folded on a ledge and holding a cup. It is the opening photograph for the Introduction (credit: WHO/Photolibrary).",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-44118/blocks/prose-sec-003",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Introduction",
      "pageStart": 13,
      "pageEnd": 17,
      "target": "../sections/sec-003-introduction.md",
      "narrative": null,
      "content": "© who/ Photolibrary\n12\nCASEBOOK ON ETHICAL ISSUES IN INTERNATIONAL HEALTH RESEARCH\nThis casebook collects 64 case studies, each of which raises an \nimportant and difficult ethical issue connected with planning, \nreviewing, or conducting health-related research. The book’s \npurpose is to contribute to thoughtful analysis of these issues \nby researchers and members of research ethics committees \n(RECs, known in some places as ethical review committees or \ninstitutional review boards), particularly those involved with \nstudies that are conducted or sponsored internationally.\nThis collection is en",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Introduces the casebook's 64 case studies, each built around one or two ethical problems in planning, reviewing or conducting health research, and intended mainly for teaching researchers and research ethics committee members, especially in international settings. The cases are short, grouped by main issue and drawn from real projects, with names, dates and places changed so that readers concentrate on the dilemmas. It also explains WHO's reasons for the book, including the educational work of its Research Ethics Review Committee and the case-based workshops held with the Harvard School of Public Health since 1999, which found that discussing cases helps limit cultural bias and leads to concrete responses.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-44118/blocks/figure-img-p017-1",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 17,
      "pageEnd": 17,
      "target": "../images/img-p017-1.webp",
      "narrative": "draft",
      "content": "Sepia-toned photograph of a woman in glasses holding a bound report marked “MASTER” in front of shelves of labelled archive binders. It is the opening photograph for the Teaching Guide (credit: WHO/TDR/Crump).",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-44118/blocks/prose-sec-004",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Teaching Guide",
      "pageStart": 17,
      "pageEnd": 37,
      "target": "../sections/sec-004-teaching-guide.md",
      "narrative": null,
      "content": "© WHO/TDR/Crump\n16\nCASEBOOK ON ETHICAL ISSUES IN INTERNATIONAL HEALTH RESEARCH\nThis brief teaching guide is intended as an aide to those using \nthese case studies in their teaching or training workshops. \nThe guide first addresses the process of teaching case studies. \nCase-based teaching differs significantly from traditional \nlectures and, therefore, requires a different approach and \nadditional skills. Because case-based teaching is typically \nused to enrich a learning experience by actively engaging \nstudents or workshop participants in structured discussions, \none of the most important sk",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A teaching guide for facilitators who use the casebook in courses and workshops on research ethics. It first covers the method of case-based teaching, stressing the facilitator's role in guiding active discussion among participants and remaining open to cases with no single right answer instead of steering towards a preferred conclusion. It then reviews the main issues raised in each chapter and suggests discussion questions, ending with themes such as how scientific misconduct should be defined, judged and reported. A short list of further resources on teaching with case studies closes the section.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-44118/blocks/prose-sec-005",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "The Case Studies",
      "pageStart": 37,
      "pageEnd": 39,
      "target": "../sections/sec-005-the-case-studies.md",
      "narrative": null,
      "content": "",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "empty"
      }
    },
    {
      "id": "library/10665-44118/blocks/figure-img-p039-1",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 39,
      "pageEnd": 39,
      "target": "../images/img-p039-1.webp",
      "narrative": "draft",
      "content": "A sepia-toned photograph of a smiling man with a young girl resting her head on his shoulder and her arm around his neck, both smiling at the camera.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-44118/blocks/prose-sec-006",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Chapter I Defining “Research”",
      "pageStart": 39,
      "pageEnd": 44,
      "target": "../sections/sec-006-chapter-i-defining-research.md",
      "narrative": null,
      "content": "Defining “Research”\n© WHO/Pierre Virot\n38\nCASEBOOK ON ETHICAL ISSUES IN INTERNATIONAL HEALTH RESEARCH\nThe need for a definition of ‘research,’ for the purposes of ethi-\ncal review, is closely related to a practical decision: what kinds \nof activities should be subject to review by a research ethics \ncommittee (REC)? But defining what is meant by ‘research’ \ninvolves matters of principle not just management. The case \nstudies in this chapter explore the boundaries of research by \nexamining what identifies research as distinct from medical \ntreatment or from other activities involving the collec",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Opens Chapter I, which asks what counts as 'research' and therefore when a research ethics committee's approval must be sought. It separates research, whose main purpose is to produce new knowledge, from medical treatment meant to benefit an individual patient and from activities such as surveillance, audit or quality improvement. The introduction warns that the pursuit of knowledge must not outweigh participants' welfare, recalling the Nazi experiments and noting risks such as the therapeutic misconception and harms from sensitive social research. It closes with suggested readings, including CDC guidance on telling public health research from non-research and an article on distinguishing audit from research.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-44118/blocks/prose-sec-007",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Case 1. SARS and airplane passengers",
      "pageStart": 44,
      "pageEnd": 45,
      "target": "../sections/sec-007-case-1-sars-and-airplane-passengers.md",
      "narrative": null,
      "content": "CASEBOOK ON ETHICAL ISSUES IN INTERNATIONAL HEALTH RESEARCH\nIn Country X, public health responsibilities are lodged in \na national centre which carries out routine surveillance \nof diseases in association with local health agencies, and \ndisseminates information as an aid to disease control and \nprevention. In March 2003, during the worldwide outbreak \nof a new human pathogen labelled severe acute respiratory \nsyndrome (SARS), the national centre aimed to systemati-\ncally identify both people with potential cases of SARS and \nany individuals who had been within contact range of those \npeople.",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Case 1 describes a national public health centre that, during the 2003 SARS outbreak, traced airline passengers who had flown with suspected cases and asked for blood samples and medical histories from healthy travellers, even though delays meant testing came after the likely incubation period. It asks whether the data were collected for surveillance, disease prevention or research, and whether ethics committee approval and informed consent were needed.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-44118/blocks/prose-sec-008",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Case 2. Evaluating sexual health and family planning programmes",
      "pageStart": 45,
      "pageEnd": 46,
      "target": "../sections/sec-008-case-2-evaluating-sexual-health-and-family-plann.md",
      "narrative": null,
      "content": "CASEBOOK ON ETHICAL ISSUES IN INTERNATIONAL HEALTH RESEARCH\nThe Institute for Family and Youth has a contract with a \nbilateral funding agency to implement family planning \nand sexually transmitted infections (STI) and HIV preven-\ntion programmes in developing countries. The funding \nis conditional on inclusion of an evaluation component. \nThrough its “Healthy Ideas!” programme, the Institute has \nrecently  established three public health prevention projects \nin  developing countries:\nü An HIV testing and counselling programme for \nadolescents with sites in one country in each of \nthree region",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Case 2 describes an institute running three donor-funded prevention projects in developing countries, covering HIV testing and counselling for adolescents, prenatal care with HIV partner notification, and a condom programme that sanctions brothel owners, each with a required evaluation. The institute argues that these low-risk operations evaluations need no ethics review, and the questions ask what separates research from programme evaluation, whether oversight is needed and how risk bears on review.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-44118/blocks/prose-sec-009",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Case 3. A treatment for central nervous system conditions",
      "pageStart": 46,
      "pageEnd": 47,
      "target": "../sections/sec-009-case-3-a-treatment-for-central-nervous-system-co.md",
      "narrative": null,
      "content": "CASEBOOK ON ETHICAL ISSUES IN INTERNATIONAL HEALTH RESEARCH\nDr W is a neurosurgeon in a hospital in one of Asia’s major \nmetropolitan centres. He earned his medical degree in that \ncity and then studied in the United States of America before \nreturning to practise in his own country. Over the past 3 \nyears, Dr W has treated more than 500 patients with central \nnervous system (CNS) conditions – including amyotrophic \nlateral sclerosis (ALS, also known as Lou Gehrig’s disease), \nParkinson’s disease, stroke, paraplegia, and tetraplegia – by \ninjecting these patients’ brains or spinal cords with o",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Case 3 describes a neurosurgeon in an Asian city who has treated over 500 patients with ALS, Parkinson's disease, stroke and paralysis by injecting olfactory cells from aborted fetuses, calling it innovative therapy. He reports stabilization and better quality of life based on videos and a patient survey but refuses placebo-controlled or sham-surgery trials, saying they would harm suffering patients. The questions ask whether this is therapy, experiment or research, whether a placebo trial would be unethical, how effectiveness could otherwise be shown and who should monitor physicians.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-44118/blocks/prose-sec-010",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Case 4. Documenting the health conditions of an indigenous community",
      "pageStart": 47,
      "pageEnd": 49,
      "target": "../sections/sec-010-case-4-documenting-the-health-conditions-of-an-i.md",
      "narrative": null,
      "content": "CASEBOOK ON ETHICAL ISSUES IN INTERNATIONAL HEALTH RESEARCH\nThe farmers and forest workers of a largely rural district of \nSouth America have recently renewed contacts with an \nisolated indigenous community in order to gain access to \ntheir natural resources. The public health agency fears that \nthis interaction will cause higher incidences of infectious \ndiseases and possibly mortality in the indigenous people. \nThe agency, therefore, invites a university research team to \nconduct an exploratory study to document the health condi-\ntions of this indigenous community. Financial resources are \nm",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Case 4 describes a university team asked, under a tight three-month funding deadline, to document the health of an isolated indigenous community in South America, which begins survey work and a photographic database while its blood sampling and genetic analysis await ethics committee approval. After a child develops meningitis and the community blames the researchers' photographs, the questions ask whether demographic data collection required approval, what safeguards isolated groups need, and what the investigators owe to children who fall ill during the study.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-44118/blocks/figure-img-p049-1",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 49,
      "pageEnd": 49,
      "target": "../images/img-p049-1.webp",
      "narrative": "draft",
      "content": "A sepia-toned close-up photograph of two young children with their heads together, one with curly hair, the other smiling at the camera.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-44118/blocks/prose-sec-011",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Chapter II Issues in Study Design",
      "pageStart": 49,
      "pageEnd": 57,
      "target": "../sections/sec-011-chapter-ii-issues-in-study-design.md",
      "narrative": null,
      "content": "Issues in Study Design\n© WHO/Christopher Black\n48\nCASEBOOK ON ETHICAL ISSUES IN INTERNATIONAL HEALTH RESEARCH\nOne of the most contentious issues in research ethics is \nwhether or not research ethics committees (RECs) should \nassess the scientific adequacy of the research protocols they \nreview. RECs typically have this responsibility (although there \nmay also be a scientific review committee constituted to do \nthis) but the way that they do it is often harshly criticized by \ninvestigators. Division of this issue into two separate ques-\ntions could therefore be useful:\nü Is it a matter of ethic",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Introduces Chapter II on study design, starting with whether research ethics committees should judge the scientific quality of the protocols they review. It argues that a study too flawed to yield knowledge cannot justify burdens on participants, yet sound design alone does not make research ethical, and a less burdensome design may have to be weighed against lower scientific value. It considers who should carry out scientific review, favouring separate review where resources allow and suitable expertise on committees where they do not, before turning to specific design questions such as placebo controls. The chapter introduction ends with annotated suggested readings on topics including clinical equipoise and the use of mystery clients.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-44118/blocks/prose-sec-012",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Case 5. Referral of severely ill children to hospital",
      "pageStart": 57,
      "pageEnd": 58,
      "target": "../sections/sec-012-case-5-referral-of-severely-ill-children-to-hosp.md",
      "narrative": null,
      "content": "CASEBOOK ON ETHICAL ISSUES IN INTERNATIONAL HEALTH RESEARCH\nGlobally, nearly 10 million children younger than 5 years die \neach year with the vast majority of these deaths occurring \nin developing countries. Seventy percent are due to acute \nrespiratory infections, diarrhoeal diseases, malaria, measles, \nmalnutrition, or some combination of these. The Integrated \nManagement of Childhood Illness (IMCI) strategy was \ndeveloped by WHO and the United Nations Children’s Fund \n(UNICEF) in 1992, with the aim of reducing the mortality and \nmorbidity associated with the major causes of childhood \nillne",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Case 5 describes a prospective study in South-East Asia tracking how many severely ill children under five referred to hospital under IMCI guidelines actually reach care, with caregiver interviews at the first-level facility and follow-up home visits, offering help to reach hospital for those who have not. It asks whether the study poses an ethical dilemma and whether researchers' presence obliges them to offer assistance, including monetary help that would not last beyond the study.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-44118/blocks/prose-sec-013",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Case 6. Negotiating safe sex practices",
      "pageStart": 58,
      "pageEnd": 59,
      "target": "../sections/sec-013-case-6-negotiating-safe-sex-practices.md",
      "narrative": null,
      "content": "CASEBOOK ON ETHICAL ISSUES IN INTERNATIONAL HEALTH RESEARCH\nDr J, a European anthropologist who has extensive experience \nin a west African country, designed a study in that country to \nexamine whether and how women involved in the sex trade \nnegotiate condom use by their male partners. Information \nabout this behaviour might help to reduce the incidence of \nHIV/AIDS in this population. The study investigated the sex \ntrade in and around places of urban entertainment (i.e. bars, \nbottle stores, and discos). Dr J was concerned that if women \nwere asked directly they might not provide truthful a",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Case 6 describes an anthropologist's study in a west African country in which research associates posed as male clients to learn how women in the sex trade negotiate condom use, approved by the health ministry's ethics committee on condition that the women were paid for lost time. An international journal later judged the deception unethical, and the case asks whether the design was justified, what the committee could have advised, whether the journal should defer to the local approval, and how results could be shared with participants.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-44118/blocks/prose-sec-014",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Case 7. Investigating treatment recommendations",
      "pageStart": 59,
      "pageEnd": 60,
      "target": "../sections/sec-014-case-7-investigating-treatment-recommendations.md",
      "narrative": null,
      "content": "CASEBOOK ON ETHICAL ISSUES IN INTERNATIONAL HEALTH RESEARCH\nAn investigator at an infectious-disease hospital in a south \nAsian country wants to know what remedies drug sellers and \npharmacists are recommending for the treatment of diar-\nrhoea, in order to develop educational materials for both the \ndrug sellers and patients. \nThe investigator believes that drug sellers would not answer \nhim truthfully if he identifies himself as a researcher before \ninterviewing them, and so decides to undertake a study \nthat requires some deception. He proposes to employ four \nyoung men, dressed as villagers",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Case 7 describes a planned study at a south Asian infectious-disease hospital in which young men posing as villagers would ask drug sellers for advice on treating a child's diarrhoea and buy what was recommended, without the sellers knowing or consenting. It asks whether sellers have a right to know they are studied, whether the investigator should intervene with those giving risky advice, how risks and community benefits compare, and whether all sellers should be debriefed.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-44118/blocks/prose-sec-015",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Case 8. Testing a new HBV vaccine",
      "pageStart": 60,
      "pageEnd": 61,
      "target": "../sections/sec-015-case-8-testing-a-new-hbv-vaccine.md",
      "narrative": null,
      "content": "CASEBOOK ON ETHICAL ISSUES IN INTERNATIONAL HEALTH RESEARCH\nOf the five hepatitis viruses, hepatitis B (HBV) is the most seri-\nous since it can cause lifelong infections that place victims at \nhigh risk of death from cirrhosis of the liver and liver cancer \n– diseases that kill about a million people every year. Chronic \nHBV infections are most common in developing countries \nwhere most people who have the virus are infected during \nchildhood through perinatal mother-to-child transmission or \nchild-to-child transmission. Vaccines have been exceptionally \neffective for preventing chronic infect",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Case 8 sets out the burden of chronic hepatitis B in developing countries and the shift from plasma-derived to recombinant vaccines because of safety concerns. It describes a randomized, double-blind trial in a large Asian country of a North American company's new recombinant vaccine, comparing it with plasma-derived vaccine and placebo in 240 infants of HBsAg-positive mothers, at a time when local vaccine coverage was below 20%. The questions ask whether a placebo arm was ethical, how the study could be improved, and whether consent from one parent was enough.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-44118/blocks/prose-sec-016",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Case 9. Tuberculosis prevention in HIV-positive people",
      "pageStart": 61,
      "pageEnd": 62,
      "target": "../sections/sec-016-case-9-tuberculosis-prevention-in-hiv-positive-p.md",
      "narrative": null,
      "content": "CASEBOOK ON ETHICAL ISSUES IN INTERNATIONAL HEALTH RESEARCH\nAlthough this case is based on research that happened \nmore than a decade ago, it is included here because similar \nethical questions arise in contemporary clinical trials.\nPulmonary Tuberculosis (TB) is a highly contagious lung \ndisease which, like the common cold, is spread by the transfer \nof germs from an infected person to a non-infected person. \nMany people infected with the TB germ, known as tubercle \nbacilli, have immune systems which “wall off” the bacilli, and \nallow the disease to lie dormant for years. Any weakening of \nth",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Case 9 explains that tuberculosis is a leading cause of death among people with HIV and that isoniazid was the standard preventive therapy for high-risk HIV-negative people, recommended in the United States for HIV-infected people but not then policy in developing countries. It describes a 1993–1995 randomized, placebo-controlled trial among 3000 HIV-positive African adults comparing placebo, six months of isoniazid and two shorter, costlier multi-drug regimens, with the placebo justified by doubts about safety and efficacy in HIV infection. The questions ask whether the placebo was justified, how it differs from no treatment, and whether testing an unaffordable regimen in Africa was appropriate.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-44118/blocks/prose-sec-017",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Case 10. Developing a vaccine for malaria",
      "pageStart": 62,
      "pageEnd": 64,
      "target": "../sections/sec-017-case-10-developing-a-vaccine-for-malaria.md",
      "narrative": null,
      "content": "CASEBOOK ON ETHICAL ISSUES IN INTERNATIONAL HEALTH RESEARCH\nIn the past decade, the rapid rise in the incidence of malaria \nhas been so alarming that it is considered a re-emerging \ndisease. In 2006 alone, an estimated 250-300 million cases \nresulted in almost a million deaths worldwide. Many of \nthose who die are children: malaria kills one child every 30 \nseconds. Countries in tropical Africa account for more than \n90% of the total malaria incidence and for the great majority \nof malaria deaths. Factors that contribute to the worsening \nglobal malaria situation include the spread of drug-res",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Case 10 describes the burden of malaria, concentrated in tropical Africa and among children, and a planned efficacy trial of a North American university's multi-stage DNA vaccine in children under five in a sub-Saharan district with strong community surveillance but very few health services. Children would be randomly chosen from the surveillance database and given vaccine or placebo double-blind, with death as the endpoint, so investigators could not treat malaria cases even though nearly all deaths could cheaply be prevented. The questions cover whether a placebo is appropriate, whether to provide treatment, other duties of care, whether death is the right measure, how ethics should shape the design, and who must ensure local ethics review.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-44118/blocks/prose-sec-018",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Case 11. Should race be listed as a risk factor?",
      "pageStart": 64,
      "pageEnd": 65,
      "target": "../sections/sec-018-case-11-should-race-be-listed-as-a-risk-factor.md",
      "narrative": null,
      "content": "CASEBOOK ON ETHICAL ISSUES IN INTERNATIONAL HEALTH RESEARCH\nRecords from the sexually transmitted infection (STI) clinic \nat the largest general hospital in a southern African country \nindicate that the segment of the population self-ascribed as \n“coloured” has twice as many cases of STIs as the segment \nthat is self-ascribed as “black”. By contrast, for almost all other \nconditions seen in the hospital’s outpatient department, the \nnumber of cases of a disease in each racial and ethnic group \nis proportional to that group’s percentage of the general \npopulation. Even after controlling for soc",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Case 11 describes a southern African STI clinic director who, seeing twice as many STI cases among people self-identified as coloured as among those identified as black, plans a survey including race and ethnicity as risk factors on the hypothesis of biological susceptibility. A community member of the ethics committee objects that the findings would reinforce stigma and questions the biological basis, and the case asks whose view is right, whether politically constructed racial categories belong in science, and how the protocol could be strengthened.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-44118/blocks/prose-sec-019",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Case 12. Short-course AZT to prevent mother-to-child transmission of HIV",
      "pageStart": 65,
      "pageEnd": 67,
      "target": "../sections/sec-019-case-12-short-course-azt-to-prevent-mother-to-ch.md",
      "narrative": null,
      "content": "CASEBOOK ON ETHICAL ISSUES IN INTERNATIONAL HEALTH RESEARCH\nThe risk of vertical transmission of HIV during pregnancy \nand delivery has been estimated at 15-30%, depending on \nseveral factors, including the stage of the mother’s illness \nand whether it has been treated. In the mid-1990s, the best-\nknown method for prevention of maternal HIV transmission \nwas the “076 regimen”, or long-course AZT treatment, in which \na pregnant HIV-positive woman received zidovudine (AZT) \nfive times a day orally from weeks 14 to 34 of the pregnancy \nand intravenously at the time of delivery. The infant would",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Case 12 recounts the placebo-controlled trials of short-course zidovudine (AZT) to prevent mother-to-child HIV transmission in sub-Saharan Africa and the Asia-Pacific, proposed because the long-course 076 regimen was seen as impractical and unaffordable there. Researchers defended the placebo as matching the local reality of no treatment and allowing faster adoption, while critics, mainly in the West, argued it breached the Declaration of Helsinki, whose placebo provisions are quoted in a footnote, and reflected a double standard. The questions ask whether donor-institution committees should insist on long-course controls, whether a likely less effective regimen should be tested, and whether a trial impossible in rich countries implies a double standard.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-44118/blocks/prose-sec-020",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Case 13. Testing an ayurvedic medicine for malaria",
      "pageStart": 67,
      "pageEnd": 69,
      "target": "../sections/sec-020-case-13-testing-an-ayurvedic-medicine-for-malari.md",
      "narrative": null,
      "content": "CASEBOOK ON ETHICAL ISSUES IN INTERNATIONAL HEALTH RESEARCH\nMalaria is a major health problem in many areas of South Asia. \nDue largely to problems of drug resistance and treatment \nfailure of chloroquine,1 a common therapy for Plasmodium \nfalciparum and Plasmodium vivax malaria,2 there is great \ninterest in exploring new drugs, drug combinations, and/or \nindigenous remedies to combat these malarial agents. \nAyush-64 is a combination of four Ayurvedic drugs which \nare mixed and then formulated into 500 mg tablets.3 This \ncombination is patented and registered to a national tradi-\ntional medici",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Case 13 describes the retesting of Ayush-64, a patented combination of four Ayurvedic drugs used for decades against malaria in South Asia but never studied for toxicity and supported only by an older study without laboratory confirmation. In a randomized trial approved by the malaria research centre's ethics committee, adults with confirmed P. vivax malaria at periurban clinics received either the national chloroquine–primaquine regimen or Ayush-64, with non-responders switched to standard treatment and no follow-up of drop-outs; footnotes explain chloroquine, the malaria species, Ayurveda and primaquine. The questions ask what evidence is needed before human testing, whether traditional therapies should be treated differently, whether the study was ethical, and what was owed to drop-outs.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-44118/blocks/prose-sec-021",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Case 14. Evaluating the use of traditional medicines for diarrhoea",
      "pageStart": 69,
      "pageEnd": 70,
      "target": "../sections/sec-021-case-14-evaluating-the-use-of-traditional-medici.md",
      "narrative": null,
      "content": "CASEBOOK ON ETHICAL ISSUES IN INTERNATIONAL HEALTH RESEARCH\nHydrocotyle asiatica, or ‘thankuni’, is a plant common to South \nAsia which, when dried, ground up, and added to water, is \nreported to be effective for treatment of bloody diarrhoea. \n‘Thankuni’ is the main ingredient of a popular traditional \nmedicine, ‘ajorno’, which is produced by a local company. \nThis medicine is widely available, very popular, and quite \ninexpensive. A paper suggesting that ‘thankuni’ decreases \nbloody diarrhoea appeared in an unrefereed journal from an \ninstitute of traditional medicine in South Asia. However,",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Case 14 concerns 'ajorno', a cheap and popular South Asian traditional medicine based on the plant thankuni, reputed to treat bloody diarrhoea but never clinically studied and of unknown chemical composition. An investigator proposes a double-blind trial against norfloxacin, the effective but often unavailable and costly antibiotic for dysentery, but the ethics committee rejects it, citing unknown composition, vague prior reports and no peer-reviewed evidence. He accuses the committee of Western bias, and the questions ask whether the committee was right, whether the bias charge holds, whether approval would imply a double standard, and how such disagreements could be mediated.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-44118/blocks/prose-sec-022",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Case 15. Twin registry genetics",
      "pageStart": 70,
      "pageEnd": 71,
      "target": "../sections/sec-022-case-15-twin-registry-genetics.md",
      "narrative": null,
      "content": "CASEBOOK ON ETHICAL ISSUES IN INTERNATIONAL HEALTH RESEARCH\nThe extent to which common mental disorders, including \nalcohol dependency and suicidal ideation, are caused by \ngenetic factors versus environmental ones remains unclear. \nPromising twin-study research on mental disorders has been \nconducted in developed countries, but such studies might \nnot be relevant for developing countries.\nCollaborating investigators from Europe and South-East \nAsia design a population twin study to be conducted in a \nSouth-East Asian country which has documented high rates \nof suicide, alcohol dependency, and",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Case 15 describes a European and South-East Asian population twin study of about 2000 twin pairs and 1000 singletons, examining genetic versus environmental causes and prevalence of common mental disorders, using interviews and cheek swabs to determine twin type, and excluding the illiterate and severely mentally ill. Participants needing treatment would be referred without follow-up, and relatives contacted for those at serious suicide risk, and the questions ask whether the exclusions are acceptable, whether referral alone meets researchers' obligations, and what is owed to twins of severely ill individuals.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-44118/blocks/prose-sec-023",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Case 16. Observing newborn care practices",
      "pageStart": 71,
      "pageEnd": 72,
      "target": "../sections/sec-023-case-16-observing-newborn-care-practices.md",
      "narrative": null,
      "content": "CASEBOOK ON ETHICAL ISSUES IN INTERNATIONAL HEALTH RESEARCH\nEach year, about four million infants in developing countries \ndie during their first month of life. Many of these deaths could \nbe prevented by improving newborn care practices such as \nproper breastfeeding, hygiene, warmth, and quick access to \nhealth care. \nA group of university researchers in an East Asian country are \nconducting an observational study that will assist them to \ndevelop means to promote more appropriate newborn care; \nthe study is being carried out in a nearby community with \na particularly high neonatal mortality",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Case 16 of the WHO casebook on ethics in international health research describes an observational study of newborn care in an East Asian community with high neonatal mortality, in which field workers are told only to record practices, and one watches a mother prepare formula with unboiled river water, diluted too much. Questions ask whether the worker should intervene and when, whether the study could have been designed to avoid the dilemma, what investigators owe participants in observational studies, and whether visitors to the household need to give consent.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-44118/blocks/prose-sec-024",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Case 17. Compassionate intervention during an observational study",
      "pageStart": 72,
      "pageEnd": 73,
      "target": "../sections/sec-024-case-17-compassionate-intervention-during-an-obs.md",
      "narrative": null,
      "content": "CASEBOOK ON ETHICAL ISSUES IN INTERNATIONAL HEALTH RESEARCH\nA field worker is conducting observations in households with \ninfants younger than 3 months in an East Asian community \nwith high infant mortality. This is being done as part of an \nobservational study to gather data to generate evidence to \npromote more appropriate newborn care. The study has been \napproved by an appropriate research ethics committee. The \nfield workers have been told to abstain from intervening and \nsimply to record what they observe. When they gave their \nconsent to the observation, the baby’s mother and a second",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Case 17 concerns a field worker in an observational newborn-care study in East Asia, instructed not to intervene, who is asked by a family to help an older child with a high fever who cannot easily be taken to a distant, poorly staffed health facility. The questions explore whether care outside a study's design can be ethically required, how observational researchers should respond to inadequate local health services, and how the field worker might balance compassion against the risk of many further requests.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-44118/blocks/figure-img-p073-1",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 73,
      "pageEnd": 73,
      "target": "../images/img-p073-1.webp",
      "narrative": "draft",
      "content": "A sepia-toned photograph of a large group of smiling and laughing children crowded together, one in front holding a white ball.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-44118/blocks/prose-sec-025",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Chapter III Harm and Benefit",
      "pageStart": 73,
      "pageEnd": 78,
      "target": "../sections/sec-025-chapter-iii-harm-and-benefit.md",
      "narrative": null,
      "content": "Harm and Benefit\n© WHO\n72\nCASEBOOK ON ETHICAL ISSUES IN INTERNATIONAL HEALTH RESEARCH\nResearch with human participants raises ethical concerns \nprecisely because the research that scientists might need \nto do in order to obtain useful knowledge might not always \nserve participants’ best interests. When scientific needs \ncoincide with participants’ interests, studies are usually \nunproblematic. In this ideal scenario, people who enrol in \nresearch gain otherwise unobtainable advantages and suffer \nno harms, and the knowledge gained in the process helps to \nimprove health care in the future and",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Introduces Chapter III on harm and benefit, asking whether the risks and gains of research are fairly shared and how participants should be chosen when a study offers advantages. It discusses the difficult task research ethics committees face in weighing burdens on participants against benefits to others, especially in early-phase drug trials, and the role of independent data and safety monitoring boards in halting trials early. The section ends with suggested readings, including works on research with children, the export of tissue samples and research in poor countries.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-44118/blocks/prose-sec-026",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Case 18. Rotavirus vaccine",
      "pageStart": 78,
      "pageEnd": 80,
      "target": "../sections/sec-026-case-18-rotavirus-vaccine.md",
      "narrative": null,
      "content": "CASEBOOK ON ETHICAL ISSUES IN INTERNATIONAL HEALTH RESEARCH\nRotavirus is one of the most common causes of severe diar-\nrhoeal disease and dehydration in infants and young children \nin both developed and developing countries. The virus, which \ninfects almost all children by the time they are aged 2 or 3 \nyears, appears to be as prevalent in high-income as in low-\nincome countries despite wide differences in the functioning \nof their sanitation and health care systems. The difference in \nincome level is instead manifested in a marked difference in \nthe morbidity and mortality rates associated wi",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Case 18 sets out the burden of rotavirus, which causes an estimated 527 000 deaths a year mostly among young children in low-income countries, and recounts how a rhesus rotavirus vaccine licensed in North America was withdrawn after reports linking it to intussusception. A developing country's ministry of health, weighing a 1 in 100 risk of rotavirus death against a 1 in 10 000 vaccine risk, asks a state-run company to produce the vaccine locally, but the manufacturer refuses to transfer the technology, leaving compulsory licensing under the TRIPS Agreement as a possible route. Questions ask whether the vaccine should be used where rotavirus kills many children, what level of risk is acceptable and who decides, and whether the manufacturer or the country has obligations regarding patent rights.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-44118/blocks/prose-sec-027",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Case 19. Pneumonia vaccine trial",
      "pageStart": 80,
      "pageEnd": 81,
      "target": "../sections/sec-027-case-19-pneumonia-vaccine-trial.md",
      "narrative": null,
      "content": "CASEBOOK ON ETHICAL ISSUES IN INTERNATIONAL HEALTH RESEARCH\nA childhood vaccine for pneumococcal disease, one of the \nmost important causes of child deaths in the developing \nworld, has been developed by a European pharmaceutical \ncompany and tested at a site in Africa. The goal of the trial \nwas to determine how many children would be protected \nfrom the disease before the age of 3 years. In this community, \nand in the region overall, approximately 90% of the childhood \ndeaths caused by pneumococcal disease occur in children \nyounger than 3 years.\nAfter community consultation and extensive ef",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Case 19 describes an African trial of a European pneumococcal vaccine in 20 000 infants, which protected 90% of vaccinated children up to age 3, after which some scientists wanted to leave controls unvaccinated to study protection in older children and long-term safety, though all controls were vaccinated. Questions ask whether those scientists were right, whether parental consent could justify withholding the vaccine, and whether further tests in older children would be justified.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-44118/blocks/prose-sec-028",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Case 20. Early termination of a trial",
      "pageStart": 81,
      "pageEnd": 82,
      "target": "../sections/sec-028-case-20-early-termination-of-a-trial.md",
      "narrative": null,
      "content": "CASEBOOK ON ETHICAL ISSUES IN INTERNATIONAL HEALTH RESEARCH\nFrom a global perspective, breast cancer is the most common \ncause of cancer deaths in women. Although breast cancer is \nincreasingly being discovered early enough for surgery to be \na beneficial intervention, many surviving women live in fear of \nrecurrence. The search for interventions to prevent this even-\ntuality has for many years been a high priority for oncologists.\nA promising drug was tested in a randomized control trial for \nwomen who had obtained maximum protection from other \ninterventions. After enrolment of the designate",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Case 20 describes a breast cancer recurrence-prevention trial in which the data safety monitoring board, seeing a strong but not statistically significant trend favouring the drug after three years, recommended stopping and offering it to all, which a leading patient organization criticised for leaving the drug's benefit uncertain. Questions ask whether the board should have acted on a trend, whether the ethics committee should have been involved, what role such boards should have, and when moral choices may override statistical significance.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-44118/blocks/prose-sec-029",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Case 21. Pregnancy in health research",
      "pageStart": 82,
      "pageEnd": 83,
      "target": "../sections/sec-029-case-21-pregnancy-in-health-research.md",
      "narrative": null,
      "content": "CASEBOOK ON ETHICAL ISSUES IN INTERNATIONAL HEALTH RESEARCH\nsuch procedures is usually quite high. In countries D and E, \nlegal abortion is available only to save the life of the woman; \nhowever, both safe and unsafe services exist at a price.\nQuestions\n1 What should the researchers do now that they know \nmany participants are becoming pregnant while \nparticipating in the study and that many are probably \nhaving illegal and perhaps unsafe abortions?\n2 Should the study sponsors provide safe abortions to \nwomen who inadvertently become pregnant while \nparticipating in the study?\n3 What if a dono",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Case 21 describes a North American NGO's trial of a vaginal microbicide to prevent HIV in high-risk women, often sex workers, in four African countries and one South Asian country, which excluded pregnant women and required monthly pregnancy tests. Many participants paused for pregnancy and returned within three months, suggesting abortions, in countries where safe legal abortion is limited or unavailable to varying degrees. Questions ask what researchers and sponsors should now do, including whether to provide safe abortion or warn of the risk, and whether such studies should be done where safe abortion is not available; in the extracted text the closing part of the case appears before its opening.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-44118/blocks/prose-sec-030",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Case 22. Acting in the face of conflicting evidence",
      "pageStart": 83,
      "pageEnd": 85,
      "target": "../sections/sec-030-case-22-acting-in-the-face-of-conflicting-eviden.md",
      "narrative": null,
      "content": "CASEBOOK ON ETHICAL ISSUES IN INTERNATIONAL HEALTH RESEARCH\nAlthough this case is based on research and a situation that \nhappened in the mid-1990s, it is included here because the \nethical questions remain relevant. See Case 34 for more \ndetails on the quinacrine trials.\nEffective and accessible methods of avoiding pregnancy \nare important not only for control of family size but also for \nreduction of maternal mortality, which has been estimated \nat over half a million deaths per year, most of which are in \ndeveloping countries. Since surgical sterilization is not readily \navailable in many l",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Case 22 recounts the controversy over non-surgical sterilization using intrauterine quinacrine, given to about 104 500 women before reports of a cancer cluster and laboratory evidence of cell mutation led to suspension of the main programme. A small group of North American population-research scientists kept promoting the drug, pointing to its effectiveness, safety and maternal deaths avoided, and organized its distribution without further studies or approval for this purpose. The questions ask whether such use can be justified where maternal mortality is high, whether drugs not registered in the exporting country should be exported to developing countries, and whether the scientists' conduct was a form of misconduct.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-44118/blocks/figure-img-p085-1",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 85,
      "pageEnd": 85,
      "target": "../images/img-p085-1.webp",
      "narrative": "draft",
      "content": "A sepia-toned photograph of a girl holding a toddler in a polka-dot dress, with a smiling young woman standing behind them holding a round object.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-44118/blocks/prose-sec-031",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Chapter IV Voluntary Informed Consent",
      "pageStart": 85,
      "pageEnd": 94,
      "target": "../sections/sec-031-chapter-iv-voluntary-informed-consent.md",
      "narrative": null,
      "content": "Voluntary Informed Consent\n© WHO\n84\nCASEBOOK ON ETHICAL ISSUES IN INTERNATIONAL HEALTH RESEARCH\n❚ THE CASE STUDIES ❚ Voluntary Informed Consent\nAlthough informed consent had appeared in codes of ethics \nfor scientific research as early as the nineteenth century,1 its \ncentral importance was firmly established in the “Doctors’ \nTrial” before the Nuremberg Tribunal at the end of the Second \nWorld War. In passing judgment on the Nazi doctors, the court \narticulated a set of principles for ethical research with human \nbeings. This ten-point statement of ethical imperatives for \nresearchers, which",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Introduces Chapter IV on voluntary informed consent, tracing its origins to the Nuremberg Code and its later development in the Declaration of Helsinki and the CIOMS guidelines. It sets out the three core elements of valid consent: capacity to decide, voluntariness and enough understandable information. The text discusses how unfamiliar research concepts can limit adults' understanding, how offers of money or free care can undermine free choice for people with no other access to them, and how some minors are able to make competent decisions. It ends with annotated readings on community engagement and consent in settings such as a vaccine trial in rural Senegal and the International HapMap Project.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-44118/blocks/prose-sec-032",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Case 23. Testing high doses of vitamin A on children",
      "pageStart": 94,
      "pageEnd": 95,
      "target": "../sections/sec-032-case-23-testing-high-doses-of-vitamin-a-on-child.md",
      "narrative": null,
      "content": "CASEBOOK ON ETHICAL ISSUES IN INTERNATIONAL HEALTH RESEARCH\n❚ THE CASE STUDIES ❚ Voluntary Informed Consent\nThe ministry of health of a West African country receives a \ngrant from a foreign medical institute to collaborate with its \ninvestigators on a double-blind study designed to assess the \neffect of periodic high doses of vitamin A on the incidences \nof childhood diarrhoea and acute respiratory infections (ARI). \nHigh-dose vitamin A capsules or placebo would be admin-\nistered in a double-blind fashion every 4 months for 1 year \nto children from 6 months to 5 years. A record of morbidity \n(",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Case 23 describes a double-blind trial of periodic high-dose vitamin A against childhood diarrhoea and acute respiratory infections in a rural West African community, where the chief and council approve the study after a public meeting but parents decline to sign consent forms and the chief threatens to expel the field team if it insists. Questions ask whether individual informed consent is a universal principle or culturally bound, whether leaders may consent for the community, when individual consent is unnecessary, and how the team and funder should respond.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-44118/blocks/prose-sec-033",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Case 24. Breast cancer in South Asia",
      "pageStart": 95,
      "pageEnd": 97,
      "target": "../sections/sec-033-case-24-breast-cancer-in-south-asia.md",
      "narrative": null,
      "content": "CASEBOOK ON ETHICAL ISSUES IN INTERNATIONAL HEALTH RESEARCH\nTHE CASE STUDIES ❚ Voluntary Informed Consent ❚\nThis case is based on research that was conducted at a \ntime when the role of tamoxifen for management of \nbreast cancer was not well defined. Currently, it is an \naccepted form of adjuvant therapy in these patients.\nResearchers from a North American university propose to \nstudy a new adjuvant therapy1 called tamoxifen2 for the \n treatment of breast cancer in premenopausal women in a \nSouth Asian country. In the United States of America, the \nstandard treatment for any stage of breast ca",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Case 24 describes a proposed trial by North American researchers in a South Asian country comparing ovary removal plus tamoxifen with no adjuvant treatment in 350 premenopausal women after breast cancer surgery, which the researchers say could not be run with a placebo arm in the United States. The principal investigator plans to leave out alternative therapies and randomization from the consent process, arguing that paternalistic medical culture there makes expressing uncertainty unacceptable, and supports this with views from South Asian immigrants, women's union officials and local physicians. Questions ask whether cultural differences justify a different consent approach, whether the outside views strengthen the case, and whether running such a study in a poor country because rich countries would not accept it is justified.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-44118/blocks/prose-sec-034",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Case 25. Testing a microbicide",
      "pageStart": 97,
      "pageEnd": 99,
      "target": "../sections/sec-034-case-25-testing-a-microbicide.md",
      "narrative": null,
      "content": "CASEBOOK ON ETHICAL ISSUES IN INTERNATIONAL HEALTH RESEARCH\nTHE CASE STUDIES ❚ Voluntary Informed Consent ❚\nExpansion of the range of woman-controlled methods to \nprevent all sexually transmitted infections (STIs) is critical to \nstemming the spread of the HIV/AIDS pandemic. A vaginal \nmicrobicide1 could offer women the potential to protect \nthemselves from HIV and other STIs. The ideal microbicide \nwould be effective, safe, acceptable, affordable, colourless, \nodourless, tasteless, easy to store and use, and available in a \nvariety of preparations. It should also be available in contra-\ncepti",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Case 25 of this casebook on ethical issues in international health research, filed under voluntary informed consent, describes a planned phase II trial by a North American feminist non-profit organization of a non-contraceptive vaginal microbicide gel among 300 HIV-negative women at family planning clinics in an African country. Participants were to use the gel or a placebo for about a year, with monthly check-ups, treatment of STIs, HIV testing every three months with counselling and the option not to receive results, referral if infected, and modest compensation. The researchers chose not to seek consent from the women's partners, which a community health committee opposed as exposing women to abuse, and the questions cover partner consent and notification, how the committee can be heard, and withholding HIV test results.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-44118/blocks/prose-sec-035",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Case 26. A study to determine the value of postoperative radiotherapy",
      "pageStart": 99,
      "pageEnd": 100,
      "target": "../sections/sec-035-case-26-a-study-to-determine-the-value-of-postop.md",
      "narrative": null,
      "content": "CASEBOOK ON ETHICAL ISSUES IN INTERNATIONAL HEALTH RESEARCH\nTHE CASE STUDIES ❚ Voluntary Informed Consent ❚\nOver an 11-year period, a well-respected cancer hospital \nin East Asia studied a much debated issue: whether the \nsurvival of patients with oesophageal cancer is improved by \nradiotherapy after resection (surgical removal of the cancer \ncells). The study did not receive an ethics review before it was \nstarted because at the time few research institutions in the \ncountry had research ethics committees.\nPatients at the hospital who underwent radical resection \nduring this period were rando",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Case 26 recounts an 11-year randomized study at a cancer hospital in East Asia, run without ethics review, comparing surgery alone with surgery plus radiotherapy for oesophageal cancer, in which patients were offered 'innovative therapy' but not told they were in an experiment because the investigators feared culturally rooted distrust of research. A North American journal published the favourable results together with a critical editorial that the authors were neither shown nor invited to answer, and the questions address the investigators' justification, harm to patients, judging past studies by today's standards and the journal's conduct.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-44118/blocks/prose-sec-036",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Case 27. Micronutrient supplementation for pregnant women",
      "pageStart": 100,
      "pageEnd": 102,
      "target": "../sections/sec-036-case-27-micronutrient-supplementation-for-pregna.md",
      "narrative": null,
      "content": "CASEBOOK ON ETHICAL ISSUES IN INTERNATIONAL HEALTH RESEARCH\n❚ THE CASE STUDIES ❚ Voluntary Informed Consent\nMaternal vitamin A deficiency is a major public health problem \nin South Asia. Premature births and small size for gestational \nage, both of which are leading risk factors for stillbirths and for \nneonatal and early childhood death, have been linked to insuf-\nficient levels of vitamin A in mothers with low socioeconomic \nstatus. A large field trial in Asia has reported a 30% reduction \nin the mortality rates of preschool children who were given \nvitamin A supplements. However, whether su",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Case 27 describes a community-randomized, placebo-controlled trial in 270 villages of a South Asian country with high poverty and illiteracy, testing whether a weekly low dose of vitamin A or beta-carotene given to married women of reproductive age reduces pregnancy-related death and illness and improves infant growth and survival. Permission came from district health officials, the study was announced by a village crier as a ministry of health initiative, and individual consent was taken only from women who became pregnant, some of whom also had detailed examinations and infant measurements. About three months in, some of the 45 000 enrolled women objected to taking a Western medicine rumoured to be ineffective, and the questions ask about the ethics of randomizing communities, the adequacy of consent and whether participants must understand randomization.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-44118/blocks/prose-sec-037",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Case 28. Breastfeeding and mother-to-child HIV transmission",
      "pageStart": 102,
      "pageEnd": 104,
      "target": "../sections/sec-037-case-28-breastfeeding-and-mother-to-child-hiv-tr.md",
      "narrative": null,
      "content": "CASEBOOK ON ETHICAL ISSUES IN INTERNATIONAL HEALTH RESEARCH\n❚ THE CASE STUDIES ❚ Voluntary Informed Consent\nThis case is based on research that took place in the 1990s \nand is not based on recent knowledge. It is included here \nbecause the ethical questions remain valid.1\nA research group based at a medical research institute in \na central African country is studying the risk for HIV infec-\ntion in children who are breastfed by HIV-infected mothers. \nShould breastfeeding by a HIV-positive mother prove to \nsignificantly increase the risk of infection in her infant, \nexisting ministry of health",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Case 28, based on research from the 1990s, describes a one-year study at a general hospital in a central African country of the risk of HIV transmission through breastfeeding, in which both partners gave consent and HIV-positive women were counselled not to breastfeed and offered free infant formula, so that those who did and did not breastfeed formed non-random comparison groups. Children were tested for HIV up to 18 months and seen every two weeks at a clinic with free medicines. When one HIV-positive woman decided to breastfeed, her husband objected and threatened court action while wanting the family to remain in the study, and the questions cover partner consent, undue inducement, whether the study was needed, its risk-benefit ratio and the investigator's role.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-44118/blocks/prose-sec-038",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Case 29. Humanized mice",
      "pageStart": 104,
      "pageEnd": 105,
      "target": "../sections/sec-038-case-29-humanized-mice.md",
      "narrative": null,
      "content": "CASEBOOK ON ETHICAL ISSUES IN INTERNATIONAL HEALTH RESEARCH\n❚ THE CASE STUDIES ❚ Voluntary Informed Consent\nLike malaria, dengue fever is a potentially fatal, mosquito-\nborne viral disease. Although dengue, with its severe, flu-like \nsymptoms, rarely causes death, dengue haemorrhagic fever, \na potentially lethal complication, has become a leading cause \nof admission to hospital and death among children in several \ntropical and subtropical countries. Vaccine development for \ndengue has been difficult because this disease can be caused \nby one of four related viruses and unless a vaccine can pro",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Case 29 describes a South American university's work towards a dengue vaccine using immunodeficient mice whose immune systems were rebuilt with umbilical-cord blood donated anonymously by about 100 women, whose consent form did not make clear that the blood would be injected into mice. A year later one donor read about 'humanized mice', complained that she felt cheated and demanded that her samples be withdrawn, and the questions ask whether she was properly informed, whether her request was reasonable and what more the women should have been told.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-44118/blocks/prose-sec-039",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Case 30. Donations for stem-cell research",
      "pageStart": 105,
      "pageEnd": 106,
      "target": "../sections/sec-039-case-30-donations-for-stem-cell-research.md",
      "narrative": null,
      "content": "CASEBOOK ON ETHICAL ISSUES IN INTERNATIONAL HEALTH RESEARCH\nTHE CASE STUDIES ❚ Voluntary Informed Consent ❚\nIn country X, the government allows the use of human \nembryos up to 14-days-old for stem-cell research. Researchers \noften acquire embryos through cooperation with clinical insti-\ntutes that provide assisted-reproduction services. Embryos \nare usually collected before a specific research study. The \ndoctor responsible for the assisted-reproduction technology \nmost commonly obtains informed consent from patients to \ndonate “spare” embryos.\nIn acquiring informed consent, the clinician firs",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Case 30 describes how, in a country that allows stem-cell research on embryos up to 14 days old, assisted-reproduction clinics use a single merged form for consent to treatment and to the donation of spare embryos, avoiding words such as donation, research and informed consent because of perceived patient sensitivities. The questions ask whether such terms may be left out, whether one form can cover both purposes, and whether consent can be given for studies not yet defined.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-44118/blocks/prose-sec-040",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Case 31. Researching health care practices and needs in an elderly population",
      "pageStart": 106,
      "pageEnd": 107,
      "target": "../sections/sec-040-case-31-researching-health-care-practices-and-ne.md",
      "narrative": null,
      "content": "CASEBOOK ON ETHICAL ISSUES IN INTERNATIONAL HEALTH RESEARCH\n❚ THE CASE STUDIES ❚ Voluntary Informed Consent\nIn recent decades, the nomadic populations of the northern \nSahara have adopted a more sedentary lifestyle, settling in \ncities and villages that were once only temporary stopovers. \nOfficials in one regional health district noticed that many \nelderly members of one of these formerly nomadic communi-\nties were admitted to hospital for conditions that were largely \npreventable or that could have been addressed more appro-\npriately, and at less cost, in outpatient clinics if they had been",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Case 31 describes a survey of health practices and needs among elderly members of a formerly nomadic Saharan community, run by a European university with a regional health district, in which researchers asked the household head's permission before interviewing older parents in private. When an 80-year-old man became unwell during a long interview, his son accused the team of making him ill, and the questions consider how this could have been avoided, whether the consent process met older people's needs, and whether ethics committees should have reviewed the survey questions.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-44118/blocks/figure-img-p107-1",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 107,
      "pageEnd": 107,
      "target": "../images/img-p107-1.webp",
      "narrative": "draft",
      "content": "A sepia-toned portrait photograph of a smiling woman with a light scarf draped over her head, wearing a nose ring and a checked top; another smiling person is out of focus on the left.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-44118/blocks/prose-sec-041",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Chapter V Standard of Care",
      "pageStart": 107,
      "pageEnd": 112,
      "target": "../sections/sec-041-chapter-v-standard-of-care.md",
      "narrative": null,
      "content": "Chapter V\n© WHO/Pierre Virot\n106\nCASEBOOK ON ETHICAL ISSUES IN INTERNATIONAL HEALTH RESEARCH\n❚ THE CASE STUDIES ❚ Standard of Care\nSome of the most contentious ethical issues in international \nhealth research arise in research studies that use a rand-\nomized controlled trial (RCT) design to test new methods and \ntreatments. This is especially true in the context of research \nthat is undertaken in developing countries in which people \nare particularly vulnerable to exploitation. In chapter II, some \nof these issues, including the use of placebo, were discussed \nin relation to the study design.",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Introduces Chapter V on the standard of care owed to control groups in randomized controlled trials, particularly in developing countries. It examines Article 32 of the 2008 Declaration of Helsinki, which requires new methods to be tested against the best proven current method except under specified conditions that permit placebo. The text contrasts a single global standard with readings based on the care available locally, noting that a strict global standard could rule out placebo-controlled trials of affordable alternatives in poor countries. It closes with suggested readings presenting differing views on uniform care requirements, double standards and the dispute over revisions to the Declaration.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-44118/blocks/prose-sec-042",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Case 32. Testing a new HIV vaccine",
      "pageStart": 112,
      "pageEnd": 114,
      "target": "../sections/sec-042-case-32-testing-a-new-hiv-vaccine.md",
      "narrative": null,
      "content": "CASEBOOK ON ETHICAL ISSUES IN INTERNATIONAL HEALTH RESEARCH\n❚ THE CASE STUDIES ❚ Standard of Care\nThis case is based on research conducted in the 1990s when \nantiretroviral drugs were not generally available in most \ndeveloping countries and the standard of care described \nhere was the prevailing standard.\nIn 1998, Vidavax, a pharmaceutical company based in \nnorthern Europe, developed an HIV vaccine that appeared \npromising. Animal studies were very successful, and phase \nI and II trials demonstrated that the vaccine was remarkably \nsafe and produced significant antibody levels in nearly all",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Case 32, set in the 1990s, describes a northern European company's planned phase III placebo-controlled trial of an HIV vaccine among intravenous drug users in a South-East Asian country, with the company providing the vaccine, equipment, computers and vehicles, and seroconverters treated under ministry standards that excluded antiretroviral drugs. Consent was a two-stage process with tests of understanding, and the protocol was approved by several ethics review bodies. An AIDS activist group condemned the lack of state-of-the-art care, while the company argued that such care would be unsustainable and an unfair inducement, and the questions ask whether the study was ethical and consider compromise positions, other services for drug users, the company's gifts and whether a local sponsor would change the assessment.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-44118/blocks/prose-sec-043",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Case 33. Short-course antiretroviral therapy in pregnant women",
      "pageStart": 114,
      "pageEnd": 115,
      "target": "../sections/sec-043-case-33-short-course-antiretroviral-therapy-in-p.md",
      "narrative": null,
      "content": "CASEBOOK ON ETHICAL ISSUES IN INTERNATIONAL HEALTH RESEARCH\n❚ THE CASE STUDIES ❚ Standard of Care\nViraret is an antiretroviral drug that is manufactured in \nEurope. A study in a southern African country was under-\ntaken to test the efficacy of the drug for prevention of \nvertical transmission of HIV when given in an innovative, \nshort-course (one dose) regimen to pregnant women who \nwere HIV-positive. The study, which was conducted under \nthe auspices of a prestigious European institute concerned \nwith prevention of transmissible diseases, aimed to offer a \nrough picture of efficacy, not to se",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Case 33 describes a European institute's trial in southern Africa of a single-dose antiretroviral regimen to prevent mother-to-child HIV transmission, whose results led WHO to endorse the drug, although later re-examination found Good Clinical Practice lapses that left too weak a basis for European licensing. An east African regulator first refused a licence because the drug was not licensed in its country of manufacture but later gave way to international pressure, and the questions ask about the relevance of the European view, other options for the regulator and WHO's role.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-44118/blocks/prose-sec-044",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Case 34. Use of quinacrine for non-surgical sterilization",
      "pageStart": 115,
      "pageEnd": 117,
      "target": "../sections/sec-044-case-34-use-of-quinacrine-for-non-surgical-steri.md",
      "narrative": null,
      "content": "CASEBOOK ON ETHICAL ISSUES IN INTERNATIONAL HEALTH RESEARCH\nTHE CASE STUDIES ❚ Standard of Care ❚\nAlthough this case is based on research that occurred \nmore than a decade ago, the issues raised by the case \nremain relevant.1\nLittle access to, and widespread non-compliance with, exist-\ning methods of contraception have led to a large unmet need \nfor better options for family planning, especially in developing \ncountries. Surgical sterilization, although safe and effective, \nis not accessible to all women who want it, especially those \nin rural or remote areas where trained staff and facilities",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Case 34 examines decades of intrauterine use of quinacrine pellets for non-surgical female sterilization, promoted as cheap and simple and used in about 104 500 women in more than 20 countries, although never approved for this purpose anywhere. It traces research since the 1960s, cancer and mutagenicity concerns that led an NGO to withdraw and leading health organizations to advise against its use, and criticism by women's groups of experimentation without adequate toxicology data or informed choice. It ends with the halt of manufacture and distribution and asks whether double standards on drug safety in contraception can be justified and who should decide.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-44118/blocks/prose-sec-045",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Case 35. Investigation of vaginal microbicides",
      "pageStart": 117,
      "pageEnd": 119,
      "target": "../sections/sec-045-case-35-investigation-of-vaginal-microbicides.md",
      "narrative": null,
      "content": "CASEBOOK ON ETHICAL ISSUES IN INTERNATIONAL HEALTH RESEARCH\nTHE CASE STUDIES ❚ Standard of Care ❚\nAn east African country has a scattered network of commu-\nnity family-planning clinics that provide free access to \nfamily-planning methods, maternity-related services, and \nsome diagnosis and care for sexually transmitted infections \n(STIs); however, patients must pay for any medications, and \nphysicians at these clinics often write prescriptions for drugs \nthat patients cannot afford. The clinics also do not offer \nPapanicolaou (Pap) smears1 for cervical cancer, since they do \nnot have the equip",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Case 35 describes a foreign-funded randomized trial of a vaginal microbicide to prevent HIV in women at East African family-planning clinics, where patients normally pay for medicines and Pap smears are unavailable. Participants would receive free STI testing and treatment, yearly Pap smears and care for unrelated illnesses during the three-year trial, but the protocol does not state whether such care would continue afterwards. An ethics committee member fears this level of care may be an unfair inducement, while women excluded from earlier trials have complained of missing out, and the questions ask how to define unfair inducement and whether the study should go ahead in that country.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-44118/blocks/figure-img-p119-1",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 119,
      "pageEnd": 119,
      "target": "../images/img-p119-1.webp",
      "narrative": "draft",
      "content": "A sepia-toned photograph of a group of young children playing and laughing outdoors on wet ground, with a boy in front pulling at his shirt and a metal bed frame behind them.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-44118/blocks/prose-sec-046",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Chapter VI Obligations to Participants and Communities",
      "pageStart": 119,
      "pageEnd": 126,
      "target": "../sections/sec-046-chapter-vi-obligations-to-participants-and-commu.md",
      "narrative": null,
      "content": "Obligations to Participants and Communities\n© WHO\n118\nCASEBOOK ON ETHICAL ISSUES IN INTERNATIONAL HEALTH RESEARCH\n❚ THE CASE STUDIES ❚ Obligations to Participants and Communities\nHealth research is increasingly understood as a partnership \nbetween interested stakeholders – potential and actual volun-\nteers and their communities, funders, sponsors, researchers, \nand health systems. In order for such a partnership to work \nwell, the expectations and obligations of each stakeholder \nmust be clear from the outset. Anticipation and negotiation \nof any health-related issues concerning the research c",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Introduces Chapter VI on what researchers and sponsors owe to participants and host communities, describing research as a partnership whose obligations should be clear from the outset. It stresses that this matters most in countries with weak health systems, where a trial may be people's only chance of care and researchers may be expected to treat them. It lists possible obligations, such as care for people excluded from or leaving trials, compensation for injury, continued treatment after a study, help with unrelated illnesses and for family members, and access to results and proven products, and asks how far the principles of beneficence and nonmaleficence should reach. Annotated readings at the end cover care and treatment in vaccine trials and whether post-trial provision of beneficial interventions should be mandatory in developing countries.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-44118/blocks/prose-sec-047",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Case 36. Observational study of cervical cancer",
      "pageStart": 126,
      "pageEnd": 128,
      "target": "../sections/sec-047-case-36-observational-study-of-cervical-cancer.md",
      "narrative": null,
      "content": "CASEBOOK ON ETHICAL ISSUES IN INTERNATIONAL HEALTH RESEARCH\n❚ THE CASE STUDIES ❚ Obligations to Participants and Communities\nAlthough this case study is based on research that took \nplace in the 1970s, the questions that it raises remain \nrelevant today.\nCervical cancer causes at least 273 000 deaths globally every \nyear, and about 85% of these deaths occur in developing coun-\ntries. The incidence of invasive cervical cancer has decreased in \ncountries where women have access to regular Papanicolaou \n(Pap) smears1 and subsequent treatment of pre-malignant \ncervical dysplasias2 readily availabl",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Presents a case, based on 1970s research, of an observational study funded by a South Asian country's medical research council to learn which cervical dysplasias progress to cancer, in order to design national control guidelines. At eight busy government hospitals, mostly illiterate women gave verbal consent to Pap smears without being told their lesions might become cancerous or that treatment existed, and those with dysplasia were followed every three months until carcinoma in situ before referral to an overloaded cancer centre. The study continued after a published longitudinal study showed all dysplasia warranted treatment, 71 women developed cancer, nine with spread, none were treated afterwards, and the case raises questions about justification, post-study care, duties arising from diagnosis, interim review, stopping rules and publication.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-44118/blocks/prose-sec-048",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Case 37. Testing a malaria vaccine",
      "pageStart": 128,
      "pageEnd": 130,
      "target": "../sections/sec-048-case-37-testing-a-malaria-vaccine.md",
      "narrative": null,
      "content": "CASEBOOK ON ETHICAL ISSUES IN INTERNATIONAL HEALTH RESEARCH\n❚ THE CASE STUDIES ❚ Obligations to Participants and Communities\nA multinational pharmaceutical company has developed \na new malaria vaccine that has been successfully tested \nin Phase I and II trials. The company commissions a team \nof investigators to conduct a randomized, double-blind, \nplacebo-controlled trial to evaluate the efficacy of the \nvaccine in combination with the standard immunization \nscheme. Ultimately, the company’s goal is to implement the \nnew vaccine in malaria-prevention programmes. Scientists \nin an east African",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Presents a case in which a multinational company plans, with scientists from an east African country, a placebo-controlled trial of a new malaria vaccine in children under five in a village with intense year-round transmission. Mothers would be recruited at a maternal and child health clinic with busy nurses helping with translation and consent checked by a standard questionnaire, while infected children would receive chloroquine under national guidelines despite 60% local resistance. Health officials object that consent is inadequate given female literacy below 40% and ask for free vaccine for all the country's children for five years if it works, which the company calls excessive, and the case asks about the ethics, the consent process, treatment and duties to the wider population.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-44118/blocks/prose-sec-049",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Case 38. Mental health problems of survivors of mass violence",
      "pageStart": 130,
      "pageEnd": 132,
      "target": "../sections/sec-049-case-38-mental-health-problems-of-survivors-of-m.md",
      "narrative": null,
      "content": "CASEBOOK ON ETHICAL ISSUES IN INTERNATIONAL HEALTH RESEARCH\n❚ THE CASE STUDIES ❚ Obligations to Participants and Communities\nMany developed countries receive a large number of refu-\ngees seeking legal asylum. Most of these countries have basic \nmental health programmes which address the psychologi-\ncal needs of refugees. Most of those programmes, however, \nare at the local level and in most countries there has been \nlittle coherent, nationwide coordination of mental health \nservices with other services for refugees, and virtually no \nmental health outreach service to refugees and victims \nof t",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Presents a case of a European university clinic treating mostly South-East Asian refugees, which plans a study of internally displaced people in the refugees' home country to develop a culturally specific diagnostic scale for post-traumatic stress disorder. The researchers, with little local experience or language, would use paid community health workers as interpreters and ethnographers, conduct anonymous one-hour home interviews about violence and trauma after verbal consent, and refer high-risk people to a government health centre visited by a psychiatrist one day a month. No services are offered and results go to the psychiatrist and ministry, and the case asks whether an ethics committee concerned about emotional upset should approve it, who benefits, whether CIOMS Guideline 5 on informing participants is met and whether referral care should be assessed or upgraded.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-44118/blocks/prose-sec-050",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Case 39. A longitudinal study of rotavirus incidence among young children",
      "pageStart": 132,
      "pageEnd": 134,
      "target": "../sections/sec-050-case-39-a-longitudinal-study-of-rotavirus-incide.md",
      "narrative": null,
      "content": "CASEBOOK ON ETHICAL ISSUES IN INTERNATIONAL HEALTH RESEARCH\n❚ THE CASE STUDIES ❚ Obligations to Participants and Communities\nAcute diarrhoeal disease is a leading cause of death in \nchildren younger than 5 years in developing countries, and \ninfants younger than 2 years are particularly susceptible. \nHowever, few prospective, community-based studies have \ndocumented the incidence and cause of diarrhoeal disease \namong children in Africa. Some hospital-based studies \nsuggest that rotavirus is a major cause of severe diarrhoea in \nAfrican countries, but the research is not adequate to confirm \nt",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Presents a case of a longitudinal, community-based study of rotavirus incidence among children under two in a densely populated, poor inner-city area of a West African city, designed by a local medical university with North American epidemiologists who fund it. A cohort of 150 infants recruited at a general hospital with oral, witnessed consent is followed for two years with cord blood, stool samples and home and monthly clinic visits. Participants receive free medical care for the child and family, antimalarial prophylaxis and transport money, all ending with the study, and the case asks how these benefits affect enrolment and outcomes, whether they should continue and whether investigators must ensure the ministry uses the findings.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-44118/blocks/prose-sec-051",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Case 40. Testing a vaccine for childhood cholera",
      "pageStart": 134,
      "pageEnd": 135,
      "target": "../sections/sec-051-case-40-testing-a-vaccine-for-childhood-cholera.md",
      "narrative": null,
      "content": "CASEBOOK ON ETHICAL ISSUES IN INTERNATIONAL HEALTH RESEARCH\n❚ THE CASE STUDIES ❚ Obligations to Participants and Communities\nCholera is an acute intestinal infection which causes watery \ndiarrhoea. If left untreated, cholera can result very quickly in \nsevere dehydration and even death. The disease is endemic in \ncertain regions of South and South-East Asia, placing young \nchildren at high risk of death from a very treatable disease. \nOral rehydration therapy (ORT) and intravenous (IV) fluids are \nvery effective for treatment of the fluid losses in cholera, such \nthat mortality from properly t",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Presents a case of a South-East Asian research institute testing a new three-dose vaccine against Vibrio cholerae O139 in children under five in a rural area of about 75 000 people, where the government clinic lacks medicines and cholera cots and health spending is 5 US dollars per person a year. Because the comparison group receives a tetanus toxoid booster and is more likely to get cholera, the institute plans a free state-of-the-art treatment facility, although some propose upgrading the government clinic instead. As the institute relies on grants and fears an unaffordable long-term commitment, the case asks who should pay for continuing care, what messages should accompany vaccination and whether participants and other citizens should receive free vaccine if it works.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-44118/blocks/prose-sec-052",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Case 41. Impact of civil war on health systems",
      "pageStart": 135,
      "pageEnd": 136,
      "target": "../sections/sec-052-case-41-impact-of-civil-war-on-health-systems.md",
      "narrative": null,
      "content": "CASEBOOK ON ETHICAL ISSUES IN INTERNATIONAL HEALTH RESEARCH\nTHE CASE STUDIES ❚ Obligations to Participants and Communities ❚\nEffective control of malaria is heavily dependent on a func-\ntioning health care system (i.e. drug distribution, information \nsystems, and preventive, curative, and referral systems). In \nsome of the countries in greatest need of malaria control, \nhowever, armed conflict has severely disrupted the structure \nof their health systems by putting strain on resources and \nincreasing the burden of disease.\nA group of researchers from the health ministry of a sub-\nSaharan Afric",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Presents a case of health ministry researchers in a sub-Saharan African country studying how armed conflict affects the health system, using focus groups with internally displaced people and host community members and interviews with leaders, officials and aid agency staff. Camps are chosen by district officials, participants are recruited by self-appointed community leaders, results go to officials who must relay them, no compensation is given, and the case asks about leader-led recruitment, duties to share results and mixing displaced and host community members in one group.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-44118/blocks/prose-sec-053",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Case 42. Determining who constitutes the community",
      "pageStart": 136,
      "pageEnd": 138,
      "target": "../sections/sec-053-case-42-determining-who-constitutes-the-communit.md",
      "narrative": null,
      "content": "CASEBOOK ON ETHICAL ISSUES IN INTERNATIONAL HEALTH RESEARCH\n❚ THE CASE STUDIES ❚ Obligations to Participants and Communities\nAn agricultural district in a South Asian country has a popu-\nlation that is 30% tribal. The tribal population of this district \ncomprises 80% of the landless poor in the country, and most \nlive in small hamlets that are 2-3 km from the main village \nin the district. Only about 10% of the tribal households own \nland, whereas the non-tribal households have landhold-\nings which provide sustenance but no significant surplus. \nRecently, because of an irrigation project, even",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Presents a case from a South Asian agricultural district where tribal people, mostly landless and living in outlying hamlets, are excluded from local power, and government health services have declined while private care is costly. A public-sector health company proposes hospital user charges, and a multilateral lender requires a participatory study in which focus group members are chosen by village committees and meet in the main village temple, finding willingness to pay if quality improves. During a gastroenteritis outbreak, field researchers meet angry tribal residents and find that under 10% of participants had tribal names, but the principal investigator dismisses their concerns, and the case asks about participant selection, who represents a community, duties toward minorities and the sponsors' obligations.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-44118/blocks/prose-sec-054",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Case 43. Evaluation research on a disability rehabilitation programme",
      "pageStart": 138,
      "pageEnd": 140,
      "target": "../sections/sec-054-case-43-evaluation-research-on-a-disability-reha.md",
      "narrative": null,
      "content": "CASEBOOK ON ETHICAL ISSUES IN INTERNATIONAL HEALTH RESEARCH\n❚ THE CASE STUDIES ❚ Obligations to Participants and Communities\nChild-rights groups in a poor democratic country in South \nAsia have successfully campaigned to make elementary \neducation for all children between the ages of 6 and 14 years a \nfundamental, justiciable right. The campaign included several \ngroups working in the area of disability, and the resulting law \non Right to Education clearly states that it applies equally to \nall children, including disabled children.\nA massive nationwide programme was launched to bring \nall chi",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Presents a case from a poor South Asian democracy where a right-to-education law covers disabled children and a national programme funds voluntary organizations 100 US dollars a year per disabled child counted by the census. A paediatrician-evaluator finds a model district's programme efficient and popular, but a new probing survey reveals many severely disabled, bedridden children missed by the census who are malnourished and lack medical care or rehabilitation. The district collector urges him to stay quiet to protect the programme, the census and the budget, while the expert believes he must expose the systematic bias, and the case asks whether he should publish, whether ethics review was needed and who is at risk in health system evaluations.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-44118/blocks/prose-sec-055",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Case 44. Clinical benefits of an immune-modifying supplement in HIV therapy",
      "pageStart": 140,
      "pageEnd": 141,
      "target": "../sections/sec-055-case-44-clinical-benefits-of-an-immune-modifying.md",
      "narrative": null,
      "content": "CASEBOOK ON ETHICAL ISSUES IN INTERNATIONAL HEALTH RESEARCH\n❚ THE CASE STUDIES ❚ Obligations to Participants and Communities\nIn 1995, two professors from prominent North American \nuniversities organized the largest randomized drug trial of \nthe past decade in HIV-infected people. With a nationwide \nteam of investigators, they evaluated the clinical benefits of \nan immune-modifying drug that was intended to supple-\nment standard treatments for HIV. Their working hypothesis \nwas that the drug could boost the immune system’s response \nto HIV. The trial was funded by a pharmaceutical company \nthat",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Presents a casebook case about a large US trial, funded by a drug company, of an immune-modifying drug added to standard HIV treatment, which an independent board stopped early after finding no clinical benefit. The company then claimed a positive effect, withheld the final data unless its own analyses were included and sought to approve publications, so the researchers published using about 95% of the data. The company sued the lead researcher's university, and the case asks who owns study data and whether sponsors may block publication of results.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-44118/blocks/prose-sec-056",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Case 45. Genetic research on an island population",
      "pageStart": 141,
      "pageEnd": 143,
      "target": "../sections/sec-056-case-45-genetic-research-on-an-island-population.md",
      "narrative": null,
      "content": "CASEBOOK ON ETHICAL ISSUES IN INTERNATIONAL HEALTH RESEARCH\nTHE CASE STUDIES ❚ Obligations to Participants and Communities ❚\nAn island nation has a population of about 90 000, all of \nwhom are of a single ethnic background. There is little or no \nimmigration to the island and hence the genetic make-up of \nthe population is quite homogenous.This presumed genetic \nhomogeneity along with the high incidence of certain \ndiseases in the population are seen as an advantage by some \nresearchers who are looking for specific alleles associated \nwith polygenic diseases.\nThe island’s government is a monar",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Case 45 describes a 2001 agreement between a European biotechnology firm and the government of a genetically homogeneous island nation of about 90 000 people with high diabetes rates, under which the firm would sample families with diabetes to search for disease genes. The company promised funding to the health ministry, a new research centre and a share of royalties, but community groups, the democracy movement and the churches objected to the lack of public debate, privacy protection and benefit guarantees and to the patenting of life forms, and the firm withdrew. The questions ask whether a population collectively owns its genetic heritage, how governments should negotiate such deals, how benefit-sharing can be judged fair, and whether a non-profit sponsor would change the ethical picture.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-44118/blocks/figure-img-p143-1",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 143,
      "pageEnd": 143,
      "target": "../images/img-p143-1.webp",
      "narrative": "draft",
      "content": "A sepia-toned photograph of a woman wrapped in a shawl and headscarf standing beside an outdoor water tap, where water pours into a large clay jar.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-44118/blocks/prose-sec-057",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Chapter VII Privacy and Confidentiality",
      "pageStart": 143,
      "pageEnd": 148,
      "target": "../sections/sec-057-chapter-vii-privacy-and-confidentiality.md",
      "narrative": null,
      "content": "Privacy and Confidentiality\n© WHO\n142\nCASEBOOK ON ETHICAL ISSUES IN INTERNATIONAL HEALTH RESEARCH\n❚ THE CASE STUDIES ❚ Privacy and Conﬁdentiality\nPrivacy and confidentiality – the first an interest or right \nof either individuals or small groups of people, and the \nsecond a duty of professionals – might be jeopardized by \nhealth research. When privacy and confidentiality can be \nfully protected without the scientific value of the research \nbeing compromised, scientists clearly have a duty to do so, \nbarring specific obstacles. In some cases, conflicts between \nthe interests of science and part",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Opens the chapter on privacy and confidentiality in a casebook on ethical issues in international health research, contrasting privacy as an interest of individuals or groups with confidentiality as a professional duty. It outlines three kinds of privacy interest (control over access to information, over being observed, and over personal decisions) and notes that what counts as an intrusion differs between cultures. It explains why both tangible interests, such as employment or insurance, and intangible ones, such as dignity and the shaping of relationships, deserve protection, and how research ethics committees should weigh risks against the value of the knowledge sought. The section ends by warning that whole communities can be stigmatized by research findings or by disclosing study sites, followed by suggested readings on returning individual results and on data protection.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-44118/blocks/prose-sec-058",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Case 46. Studying Nevirapine in West Africa",
      "pageStart": 148,
      "pageEnd": 149,
      "target": "../sections/sec-058-case-46-studying-nevirapine-in-west-africa.md",
      "narrative": null,
      "content": "CASEBOOK ON ETHICAL ISSUES IN INTERNATIONAL HEALTH RESEARCH\n❚ THE CASE STUDIES ❚ Privacy and Conﬁdentiality\nA study in a West African country is designed to examine the \neffectiveness of the antiretroviral drug, Nevirapine, when \nadministered to HIV-positive women during labour and then \nto their newborns for the first three months after birth. The \naim of the study is to assess whether Nevirapine can reduce \nthe perinatal transmission of HIV infection in infants aged \nyounger than one year.\nPregnant women have their blood drawn and tested for HIV \nin the latter stages of pregnancy. They are a",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Presents a case from a West African study of nevirapine to prevent perinatal HIV transmission, in which an HIV-positive woman, one of several wives, refuses to let the doctor tell her husband for fear of being expelled or harmed. Colleagues disagree on whether the promised confidentiality should be broken, and the questions ask whether the husband or other partners should be told and whether a safety plan is owed to the woman.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-44118/blocks/prose-sec-059",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Case 47. The quality of care in a family welfare programme",
      "pageStart": 149,
      "pageEnd": 150,
      "target": "../sections/sec-059-case-47-the-quality-of-care-in-a-family-welfare.md",
      "narrative": null,
      "content": "in one of the states of a South Asian country. The project is \nfunded by a grant from a European university to the South \nAsian university which employs the researchers. As part of \nthe evaluation process, the investigators plan to interview \nthe doctors, supervisors, and multipurpose health workers \nemployed at selected primary health centres (PHCs) in the \nstate, and the family-planning clients who visit those PHCs. \nClient-provider interactions at the centres, and at a sterili-\nzation camp organized by one of the selected PHCs, will be \nobserved for one week.\nAn ethical review board, conven",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Presents a case on evaluating care in a South Asian family welfare programme, where an ethics board required that primary health centres and staff not be identifiable, and a field researcher saw syringes being reused. After she reported it anonymously to a supervisor, she saw the same practice a week later, and the questions ask whether confidentiality should be strictly upheld and what the principal investigator should do.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-44118/blocks/prose-sec-060",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Case 48. Responding when study findings are challenged",
      "pageStart": 150,
      "pageEnd": 151,
      "target": "../sections/sec-060-case-48-responding-when-study-findings-are-chall.md",
      "narrative": null,
      "content": "CASEBOOK ON ETHICAL ISSUES IN INTERNATIONAL HEALTH RESEARCH\n❚ THE CASE STUDIES ❚ Privacy and Conﬁdentiality\nA team of university researchers have completed an evalua-\ntion of the quality of care in a family welfare programme of \na state in a South Asian country. The researchers complied \nwith the recommendations of a research ethics committee \nthat they should ensure the confidentiality of all identifying \ndata about the primary health centres (PHCs) – which deliver \nthe programme – and their employees: all information which \ncould later be used by authorities to identify specific PHCs \nor emp",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Presents a related case in which researchers who found widely varying quality of care, and poor conditions at sterilization camps, in a South Asian state's primary health centres refused officials' demands to name the centres, citing the agreed anonymity. Officials accused them of fabricating evidence and argued confidentiality did not apply, and the questions ask whether the centres should be named and when confidentiality promises may be set aside.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-44118/blocks/prose-sec-061",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Case 49. Determining post-abortion complication levels",
      "pageStart": 151,
      "pageEnd": 153,
      "target": "../sections/sec-061-case-49-determining-post-abortion-complication-l.md",
      "narrative": null,
      "content": "CASEBOOK ON ETHICAL ISSUES IN INTERNATIONAL HEALTH RESEARCH\nTHE CASE STUDIES ❚ Privacy and Conﬁdentiality ❚\nAn eastern European country has passed a law to make \nabortion legal for a range of social and medical indications. \nNevertheless, legal abortion centres are neither geographi-\ncally accessible, nor always functioning effectively. Indeed, \nabortions outside of the legally recognized sector are \nstill estimated to occur between two and five times more \nfrequently than do those in legally recognized centres.\nAlthough the demographic profile of abortion-seekers, \nthe dangers associated with",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Presents a case on a study in an Eastern European country, where many abortions still occur outside legal centres, designed to measure post-abortion complications and link them to the type of provider across 140 villages. Women are found through providers, community health workers and women's groups, give oral consent, and are interviewed at home with safeguards such as dummy interviews, a focus on general gynaecological health and artificial privacy. One member of the funder's ethics committee doubts that identifying records will stay confidential, and the questions ask whether recruitment, oral consent and the interview methods adequately protect privacy and avoid coercion.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-44118/blocks/prose-sec-062",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Case 50. Evaluating the cost-benefit ratio of long-term care services",
      "pageStart": 153,
      "pageEnd": 154,
      "target": "../sections/sec-062-case-50-evaluating-the-cost-benefit-ratio-of-lon.md",
      "narrative": null,
      "content": "CASEBOOK ON ETHICAL ISSUES IN INTERNATIONAL HEALTH RESEARCH\nTHE CASE STUDIES ❚ Privacy and Conﬁdentiality ❚\nThe mental health institute of a Central American country \nhas historically offered financial support to community \nmental health centres (CMHCs) that provide care for people \nwho have severe, chronic mental illness (including most \nindividuals with schizophrenia, and many who suffer from \nmanic-depressive illness and chronic major depression). The \ninstitute has given this support in the form of reimburse-\nments to CMHCs for long-term care services, which typically \ninclude supervision",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Presents a case in which a Central American mental health institute, seeking to compare the cost and benefit of long-term community care services, told centres to obtain patients' consent to release confidential psychiatric records and to reimburse care only for those who signed. Clinicians called this coercive and objected to government access to records, and the questions ask when state access to medical records is acceptable and what makes consent valid.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-44118/blocks/prose-sec-063",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Case 51. Research on an identifiable population",
      "pageStart": 154,
      "pageEnd": 155,
      "target": "../sections/sec-063-case-51-research-on-an-identifiable-population.md",
      "narrative": null,
      "content": "CASEBOOK ON ETHICAL ISSUES IN INTERNATIONAL HEALTH RESEARCH\n❚ THE CASE STUDIES ❚ Privacy and Conﬁdentiality\nA team of molecular biology researchers wishes to study \nthe basis of alcoholism in selected native peoples of North \nAmerica. This research is based on reports of a significant \ncorrelation between alcoholism and several forms of brain-\nwave activity that are measurable by electroencephalography: \nCaucasian and African Americans with these brainwave \npatterns have a higher risk of alcoholism. There is also some \nevidence of a genetic linkage between the brainwaves and \ntraits of alcohol",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Presents a case in which researchers plan to study a genetic link between brainwave patterns and alcoholism in 300 families of a North American indigenous tribe, offering payment, and many individuals want to take part. A tribal representative body urges the ethics committee to reject the study for lack of consultation, disregard for beliefs about the sacredness of blood and the risk of stigma, and the questions ask how the committee should weigh community and individual views.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-44118/blocks/prose-sec-064",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Case 52. Case-control study of vasectomy and prostate cancer",
      "pageStart": 155,
      "pageEnd": 156,
      "target": "../sections/sec-064-case-52-case-control-study-of-vasectomy-and-pros.md",
      "narrative": null,
      "content": "CASEBOOK ON ETHICAL ISSUES IN INTERNATIONAL HEALTH RESEARCH\nTHE CASE STUDIES ❚ Privacy and Conﬁdentiality ❚\nEpidemiologists in an industrialized country propose to \ninvestigate the association between vasectomy and adeno-\ncarcinoma1 of the prostate gland, using a case-control study \ndesign. Men with prostate cancer, confirmed by histologi-\ncal examination, will be identified through their clinicians’ \nrecords. The control group, consisting of men of similar ages \nwho do not have prostate cancer, will be chosen at random \nfrom the national election registry. Since the country in \nquestion has g",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Presents a case-control study in an industrialized country on vasectomy and prostate cancer, in which cases are identified from clinicians' records, controls are drawn from the electoral register, and participants are interviewed by telephone. To avoid bias, men would be told only that the study concerns risk factors for prostate disease, and the questions ask whether record access without permission, telephone consent and withholding the study's purpose are acceptable.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-44118/blocks/prose-sec-065",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Case 53. Studying health-seeking behaviour",
      "pageStart": 156,
      "pageEnd": 157,
      "target": "../sections/sec-065-case-53-studying-health-seeking-behaviour.md",
      "narrative": null,
      "content": "CASEBOOK ON ETHICAL ISSUES IN INTERNATIONAL HEALTH RESEARCH\n❚ THE CASE STUDIES ❚ Privacy and Conﬁdentiality\nA team of social scientists concerned with improvement of \nwomen’s health wants to learn why women do not return to \nthe hospital for the results of Papanicolaou (Pap) tests.1 They \nhave a research project to follow up with women who have a \npresumptive diagnosis of cervical cancer (a positive Pap test) \nbut who do not return to the hospital, as advised, to receive \ntheir test results. The aim of the research is to find out how to \nimprove services to these women.\nThe chiefs of service i",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Presents a case in which social scientists, with hospital permission, use records to find women with positive Pap tests who did not return for results, visit them at home, give them their results and refer them directly to physicians. They justify this by the health benefits and the hospital's ownership of records, and the questions ask whether confidentiality is breached and how else the problem could have been approached.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-44118/blocks/prose-sec-066",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Case 54. Health promotion survey research on a commercial farm",
      "pageStart": 157,
      "pageEnd": 159,
      "target": "../sections/sec-066-case-54-health-promotion-survey-research-on-a-co.md",
      "narrative": null,
      "content": "CASEBOOK ON ETHICAL ISSUES IN INTERNATIONAL HEALTH RESEARCH\nTHE CASE STUDIES ❚ Privacy and Conﬁdentiality ❚\nA large farm in southern Africa recruits both men and women \nas seasonal labourers from the nearby town, local villages and \nother rural areas. The male-female ratio among the seasonal \nlabourers is approximately four to one, although other women \nare involved informally in the economy of the farm selling \nvegetables, game meat, tea, wine, and beer to farm workers in \nand around the farm. Most of the women employed as seasonal \nworkers are younger than 25 years, and 70% are single.\nOnly",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Presents a case set on a commercial farm in southern Africa, where mostly male migrant seasonal workers live in compounds with few women, and health promotion researchers returned for a follow-up survey after agreeing their role with management and workers. Mapping showed hidden sexual contact between migrant men and local women, and registration revealed that about 8% of workers were under 16, most of them local girls aged 8 to 15. The researchers feared these girls faced sexually transmitted infections including HIV and were missing school, and the questions ask whether they should inform management and what obligations they have to protect participants.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-44118/blocks/prose-sec-067",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Case 55. Interviewing child domestic helpers in sub-Saharan Africa",
      "pageStart": 159,
      "pageEnd": 161,
      "target": "../sections/sec-067-case-55-interviewing-child-domestic-helpers-in-s.md",
      "narrative": null,
      "content": "CASEBOOK ON ETHICAL ISSUES IN INTERNATIONAL HEALTH RESEARCH\nTHE CASE STUDIES ❚ Privacy and Conﬁdentiality ❚\nincluding the risk of harassment or a beating, the children \nwill be interviewed in private. Each interviewer will have a \nseparate “safe” questionnaire to revert to should the child’s \n“employer” enter the room unexpectedly, and the child will \nhave been prepared for this possibility. The interviewers will \ngive the children their contact details and information about \nhow to contact a psychologist who is working on the study \nwith them. Both the employers and the house helpers will be",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Presents Case 55, a questionnaire study of reproductive health problems among girls aged 13–17 who live away from home as domestic workers in sub-Saharan Africa, set against the background of child fosterage being misused for trafficking. It describes how households are approached, how children give consent and are interviewed privately with a decoy questionnaire, contact details and compensation, and then asks whether privacy, safety and valid consent have been adequately addressed.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-44118/blocks/figure-img-p161-1",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 161,
      "pageEnd": 161,
      "target": "../images/img-p161-1.webp",
      "narrative": "draft",
      "content": "A sepia-toned photograph of a woman with windblown hair beside a young child wearing a fur-trimmed hat and fur coat.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-44118/blocks/prose-sec-068",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Chapter VIII Professional Ethics",
      "pageStart": 161,
      "pageEnd": 167,
      "target": "../sections/sec-068-chapter-viii-professional-ethics.md",
      "narrative": null,
      "content": "Chapter VIII\n© WHO\n160\nCASEBOOK ON ETHICAL ISSUES IN INTERNATIONAL HEALTH RESEARCH\n❚ THE CASE STUDIES ❚ Professional Ethics\nThe expectation that researchers and other stakeholders in \nthe research process – including ethics committee members, \nsponsors, and funders – will act with integrity and honesty \nis a fair one. When a research article is published, it is fair to \nexpect, at the very least, that the data has not been fabricated, \nfalsified, or plagiarized; that results are correctly reported; \nthat the disclaimers about conflicts of interest are complete \nand correct; that a thorough and",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Opens the chapter on professional ethics in a casebook on ethical issues in international health research, setting out what can fairly be expected of researchers, ethics committee members, sponsors and funders in terms of integrity and honesty. It focuses on two broad areas, conflicts of interest and scientific misconduct, defining a conflict of interest as a situation where personal gain could compromise duties to participants or to sound science, and separating this from the tension between patient care and good science. It explains how industry-funded research and scientists' financial ties to companies have made such conflicts widespread, and discusses concerns about commercial research ethics committees and fees charged by committees. The section closes with suggested readings on industry relationships, whistleblowing and cross-cultural views of scientific misconduct.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-44118/blocks/prose-sec-069",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Case 56. Testing delivery methods for a hormonal contraceptive",
      "pageStart": 167,
      "pageEnd": 168,
      "target": "../sections/sec-069-case-56-testing-delivery-methods-for-a-hormonal.md",
      "narrative": null,
      "content": "CASEBOOK ON ETHICAL ISSUES IN INTERNATIONAL HEALTH RESEARCH\nTHE CASE STUDIES ❚ Professional Ethics ❚\nThe manufacturer of a new hormonal contraceptive commis-\nsions a research team to design a clinical trial to compare the \neffectiveness and tolerability of the new preparation using \nthree different methods of delivery – oral tablets, transder-\nmal patches, and injections. The manufacturer also wants the \nresearchers to focus on the use of this new contraceptive in \nwomen of two different socioeconomic groups. The working \nhypothesis is that the delivery of hormonal contraceptives by \ntransderm",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Case 56 describes a manufacturer-sponsored trial comparing tablet, patch and injectable forms of a new hormonal contraceptive in women from two socioeconomic groups, with the company paying researchers' salaries, computers and a per-participant fee and giving volunteers a small payment. Questions ask about the appropriateness of these benefits, conflicts of interest, partner involvement in consent, infections acquired during the trial and the sponsor's obligations if the product fails.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-44118/blocks/prose-sec-070",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Case 57. Testing a treatment for schizophrenia",
      "pageStart": 168,
      "pageEnd": 169,
      "target": "../sections/sec-070-case-57-testing-a-treatment-for-schizophrenia.md",
      "narrative": null,
      "content": "CASEBOOK ON ETHICAL ISSUES IN INTERNATIONAL HEALTH RESEARCH\n❚ THE CASE STUDIES ❚ Professional Ethics\nAn Asian pharmaceutical company has developed a prom-\nising new antipsychotic medication for the treatment of \n schizophrenia.1 Sales analysts predict the drug could earn the \ncompany a substantial profit within four years. The study drug \nhas already been tested on several thousand volunteers in Asia. \nDuring this testing, however, some study participants devel-\noped cardiac arrhythmias. Consequently, the regulatory agency \nresponsible issued a “not approvable” letter, which requires the \ndrug",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Case 57 describes an Asian drug company that, after a regulator refused approval of its antipsychotic over heart rhythm problems, contracts an overcrowded eastern European psychiatric hospital to test it, with doctors paid per recruited patient and local regulators not told of the earlier refusal. Questions cover risk-benefit, disclosure duties across countries, ensuring capacity to consent, possible misconduct, recruiters' conflicts of interest and post-trial access.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-44118/blocks/prose-sec-071",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Case 58. Budget reviews by research ethics committees",
      "pageStart": 169,
      "pageEnd": 170,
      "target": "../sections/sec-071-case-58-budget-reviews-by-research-ethics-commit.md",
      "narrative": null,
      "content": "CASEBOOK ON ETHICAL ISSUES IN INTERNATIONAL HEALTH RESEARCH\nTHE CASE STUDIES ❚ Professional Ethics ❚\nA major North American university has submitted a research \nproposal to the research ethics committee of the National \nUniversity School of Medicine (NUSM) in a developing coun-\ntry in South-East Asia. It is an ambitious proposal that carries \nwith it a US$ 500 000 yearly budget to examine the efficacy \nof an innovative national family planning programme The \nproposal includes bringing researchers to North America for \nshort-term training on new family planning strategies, low-\ncost surgeries,",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Case 58 describes a research ethics committee at a South-East Asian medical school that refuses to review a large North American family planning study unless it sees the budget, while the North American university fears the school's 10% overhead could sway members who are also on the research team. Questions ask whether budget review belongs to an ethics committee, how any conflict of interest could be handled and how capacity-building benefits should be weighed.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-44118/blocks/prose-sec-072",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Case 59. Determining the workforce costs of the AIDS epidemic",
      "pageStart": 170,
      "pageEnd": 172,
      "target": "../sections/sec-072-case-59-determining-the-workforce-costs-of-the-a.md",
      "narrative": null,
      "content": "CASEBOOK ON ETHICAL ISSUES IN INTERNATIONAL HEALTH RESEARCH\n❚ THE CASE STUDIES ❚ Professional Ethics\nThe staff-benefits group of a west African mining company \nasks a research team based at a European university to help \ndetermine the economic impact of the AIDS epidemic on their \nworkforce. The group wants to convince senior management \nthat the cost is much higher than expected. They suspect that \nabsenteeism due to AIDS, rapid turnover of highly trained \nand semi-skilled staff (which generates retraining costs), \ntreatment costs associated with the illness, and one-time \nbenefits and funera",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Case 59 describes a European university team, fully funded by a west African mining company, studying the cost of AIDS to the company's workforce in the hope of prompting prevention programmes. A trade union official warns that the company may instead dismiss HIV-positive workers or downsize, and the company refuses to give written assurances. After the findings show rising health care costs, the chief executive asks the team to recommend capping HIV insurance benefits, and questions ask how researchers should guard against misuse of their data and respond to such pressure.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-44118/blocks/prose-sec-073",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Case 60. Action research on involuntary resettlement",
      "pageStart": 172,
      "pageEnd": 174,
      "target": "../sections/sec-073-case-60-action-research-on-involuntary-resettlem.md",
      "narrative": null,
      "content": "CASEBOOK ON ETHICAL ISSUES IN INTERNATIONAL HEALTH RESEARCH\n❚ THE CASE STUDIES ❚ Professional Ethics\nA small community-based NGO has been delivering a health \nprogramme in the slums of a large city in South Asia. Part \nof the slum’s population has been relocated to another \ncolony, 15 km away, and the NGO has set up a clinic in this \nnew colony. Based on their experience with the community \nboth before and after relocation, the NGO staff members are \nconvinced that the process of resettlement has damaged \neven further the lives of the people who have been relocated. \nTo expose the living condi",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Case 60 describes a small NGO in a South Asian city that partners with a research organization to study how relocation from slums to a distant colony has affected people's health, education and livelihoods. The ethics committee bars recruiting case-study participants from the NGO's clinic users for fear they would feel coerced, so the team runs a random household survey, but by identifying with the NGO it faces pressure to give direct help and participants expect services. Questions concern the committee's decision, how far to meet community expectations, effects on informed consent and the tension between action and research.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-44118/blocks/prose-sec-074",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Case 61. Victimizing the system or a victim of it?",
      "pageStart": 174,
      "pageEnd": 176,
      "target": "../sections/sec-074-case-61-victimizing-the-system-or-a-victim-of-it.md",
      "narrative": null,
      "content": "CASEBOOK ON ETHICAL ISSUES IN INTERNATIONAL HEALTH RESEARCH\n❚ THE CASE STUDIES ❚ Professional Ethics\nXue Lee, a 25-year-old research assistant with plans to go to \nmedical school, has discovered that a set of data given to her \nby a much-admired senior researcher, Dr Simpson, does not \nsupport the working hypothesis of their lab, which is that the \nincreased vulnerability to cardiovascular disease that accom-\npanies ageing is due to changes in the ratio of different levels \nof lipids or fats in the blood.\nMs Lee shows the unexpected results to Dr Simpson, who \ntakes the file home with him to r",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Case 61 describes a young research assistant who finds that a respected senior researcher altered data that contradicted their lab's hypothesis, and then uncovers a wider pattern of fabricated measurements and non-existent patients. Despite a colleague's warning that everyone will lose, she files a formal complaint, and an inquiry leads the researcher, a major grant earner, to plead guilty to falsifying a federal grant application after more than a decade of fraud. Questions ask whether his pleas for leniency are valid, how whistle-blowers should be treated and who should enforce scientific integrity.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-44118/blocks/prose-sec-075",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Case 62. Truth and consequences",
      "pageStart": 176,
      "pageEnd": 177,
      "target": "../sections/sec-075-case-62-truth-and-consequences.md",
      "narrative": null,
      "content": "CASEBOOK ON ETHICAL ISSUES IN INTERNATIONAL HEALTH RESEARCH\n❚ THE CASE STUDIES ❚ Professional Ethics\nSix graduate students who work under Professor Maria Kieros \nin the department of genetics at a major university have \nreluctantly come to the conclusion that she has been faking \ndata. This conclusion is based on a number of direct and indi-\nrect observations. In reading a grant application, for example, \nMs Heath, one of the graduate students, has noted that some \ndata was represented as if it were unpublished data even \nthough it had appeared in an earlier paper published by the \nlaboratory.",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Case 62 describes six genetics graduate students who suspect their professor of faking data, confront her, and after months of hesitation over the risk to their own research report her to the university. An investigation finds falsified grant applications and pressure on students to hide unwanted results, and after the professor resigns most students must restart their projects, leave or face years of delay. Questions ask whether they should have reported, what would have happened had they stayed silent and how universities should protect whistle-blowers.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-44118/blocks/prose-sec-076",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Case 63. The curious career of Dr Taylor",
      "pageStart": 177,
      "pageEnd": 179,
      "target": "../sections/sec-076-case-63-the-curious-career-of-dr-taylor.md",
      "narrative": null,
      "content": "CASEBOOK ON ETHICAL ISSUES IN INTERNATIONAL HEALTH RESEARCH\nTHE CASE STUDIES ❚ Professional Ethics ❚\nFor almost three decades, Dr Taylor had a prosperous career \nat a well-respected North American university, during which \nhe became a world-renowned expert in the fields of nutri-\ntion and immunology. He was often nominated for, and had \nreceived, prestigious awards and recognitions.\nWhile at the university, Dr Taylor was asked by a company \nbased in the United States of America, Blake Pharmaceuticals, \nto undertake a large study to test whether their new infant \nformula could help babies avoid",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Case 63 describes a renowned nutrition researcher whose infant formula studies, involving hundreds of supposed babies, are found by an independent panel to have never been carried out, yet his university takes no action after he threatens to sue. He goes on to publish an implausible study of his own patented multivitamin and memory in older people, later supported only by an untraceable author in his own journal, and he retires to promote the product. Questions ask about the university's duties, whether an ethics committee may weigh a researcher's credibility, and the roles of government, professional societies and journals in addressing fraud.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-44118/blocks/prose-sec-077",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Case 64. Whose idea is it, anyway?",
      "pageStart": 179,
      "pageEnd": 181,
      "target": "../sections/sec-077-case-64-whose-idea-is-it-anyway.md",
      "narrative": null,
      "content": "CASEBOOK ON ETHICAL ISSUES IN INTERNATIONAL HEALTH RESEARCH\nTHE CASE STUDIES ❚ Professional Ethics ❚\nDr Ruiz is a very productive physician-scientist at a Central \nAmerican medical research institute in country A, and has \ncompleted more than 15 studies and published more than \n20 papers. More than 70% of the protocols he has submit-\nted for funding have been approved and implemented. After \n5 years, he returns to his home country (country B, also in \nCentral America), leaving behind several ongoing, unfinished \nstudies in the hands of his co-investigators. He also leaves \nbehind unfunded prot",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Case 64 describes a Central American physician-scientist who, asked by an international funder to review a proposal, recognises it as a near copy of an unfunded protocol he wrote with co-investigators at his former institute in another country. The funder rejects the proposal but, after an internal review that never contacts him, finds only possible negligence and treats the protocol as public domain. Questions ask whether the matter was handled fairly, whether a different standard applied to a developing-country researcher, which ethical standards apply, and who owns research ideas and deserves authorship.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-44118/blocks/prose-sec-078",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Glossary",
      "pageStart": 181,
      "pageEnd": 195,
      "target": "../sections/sec-078-glossary.md",
      "narrative": null,
      "content": "Action Research: see Research design\nAdjuvant therapy: Treatment that is given in addition to the \nprimary treatment. For example, adjuvant therapy for cancer \nusually refers to surgery followed by chemotherapy or radio-\ntherapy to help decrease the risk of the cancer coming back.\nAdenocarcinoma: a malignant tumor originating in glandu-\nlar (secretary) tissue.\nAdverse event (AE): In the context of a clinical trial, any unto-\nward medical occurrence in a patient or clinical investigation \nsubject administered a pharmaceutical product and which \ndoes not necessarily have a causal relationship wi",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The glossary of the Casebook on ethical issues in international health research, defining in alphabetical order the medical, research-design and ethics terms used in the book, mostly drawn from WHO publications with other sources cited. The visible entries run from action research, adjuvant therapy, adverse events and adverse drug reactions through anonymization, audit, ayurveda, beneficence and blinding. The end covers terms such as tuberculosis, vasectomy, vertical transmission, vulnerable research participants and whistleblowing.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-44118/blocks/prose-sec-079",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Suggested readings and resources",
      "pageStart": 195,
      "pageEnd": 210,
      "target": "../sections/sec-079-suggested-readings-and-resources.md",
      "narrative": null,
      "content": "The readings and resources listed here are organized under \nthe following headings:\n1. Those related to guidelines and guidance on \nethics regulations\n2. Literature on Ethics Review Committees\n3. Literature on ethics and international health research\n4. Suggested reading by chapter (this reading list also \nappears at the end of each chapter)\nü\u0003 Chapter I Defining “Research”: When must an ethics \ncommittee’s approval be sought?\nü\u0003 Chapter II Issues in Study Design: Designing \nscientifically (and ethically) sound studies\nü\u0003 Chapter III Harm, Benefit and Just Allocation: Are \nresearch benefits an",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The annotated list of suggested readings and resources of the Casebook on ethical issues in international health research, organised into international guidelines and guidance, literature on ethics review committees, literature on ethics in international health research, and readings for each of the book's eight chapters. It opens with websites that compile national research regulations and with key guidance such as the CIOMS guidelines, the Oviedo Convention and ICH Good Clinical Practice, and ends with readings on conflicts of interest, whistleblowing and scientific misconduct.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-44118/blocks/prose-sec-080",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Appendix",
      "pageStart": 210,
      "pageEnd": 212,
      "target": "../sections/sec-080-appendix.md",
      "narrative": null,
      "content": "The ethical principles included here are reprinted from the \nInternational Ethical Guidelines for Biomedical Research Involving \nHuman Subjects, prepared by the Council for International \nOrganizations of Medical Sciences (CIOMS) in collaboration \nwith the World Health Organization.1 While these principles \nare widely known and referred to, it is important to recognize \nthat there are additional and alternative principles that provide \nuseful conceptual and practical frameworks.\nGENERAL ETHICAL PRINCIPLES\nAll research involving human subjects should be conducted \nin accordance with three basic",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The appendix of the Casebook reprints the general ethical principles from the CIOMS International Ethical Guidelines for Biomedical Research Involving Human Subjects, noting that other principles also offer useful frameworks. It sets out respect for persons, covering autonomy and protection of those with diminished autonomy, beneficence, including non-maleficence, and justice, understood mainly as fair distribution of the burdens and benefits of research with special protection for vulnerable people. It adds that research should leave low-resource countries no worse off, respond to their health needs and use the least vulnerable participants necessary, and closes with the ISBN and a note that the publication came from a WHO Research Ethics Review Committee project with the University of Geneva.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    }
  ]
}
